[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 979
1. Rao SA, Santosh V, Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol; 2010 Oct;23(10):1404-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.
  • Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).
  • Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.
  • We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.
  • More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.
  • The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).
  • Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711171.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


2. Khwaja FW, Duke-Cohan JS, Brat DJ, Van Meir EG: Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res; 2006 Nov 1;12(21):6331-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration.
  • The goal of our study was to find reliable markers that could be used for disease monitoring as well as to identify new targets for the therapeutic intervention for malignant astrocytoma (WHO grades 3 and 4).
  • EXPERIMENTAL DESIGN: We employed proteomic techniques to identify secreted proteins in the cerebrospinal fluid that were specific to patients with malignant astrocytoma.
  • RESULTS: Among 60 cerebrospinal fluid samples of patients with various central nervous system diseases, attractin was consistently found to be elevated in the samples of patients with malignant astrocytoma.
  • To independently validate these results, we examined attractin expression in a new set of 108 normal and tumoral brain tissue specimens and found elevated expression in 97% of malignant astrocytomas, with the highest levels in grade 4 tumors.
  • Using immunohistochemistry, we further showed that attractin is produced and secreted by the tumor cells.
  • Finally, we showed that cerebrospinal fluid from brain tumor patients induces glioma cell migration and that attractin is largely responsible for this promigratory activity.
  • CONCLUSIONS: Our results find attractin to be a reliable secreted marker for high-grade gliomas.
  • Additionally, our migration studies suggest that it may be an important mediator of tumor invasiveness, and thus, a potential target in future therapies.
  • [MeSH-major] Astrocytoma / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Cell Movement / physiology. Glioma / cerebrospinal fluid. Membrane Proteins / cerebrospinal fluid
  • [MeSH-minor] Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085642.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 86335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATRN protein, human; 0 / Membrane Proteins
  •  go-up   go-down


3. Jang SY, Kong MH, Song KY, Frazee JG: Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult. J Korean Neurosurg Soc; 2009 Jun;45(6):381-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult.
  • The first case of intracranial metastases of a cervical intramedullary low-grade astrocytoma without malignant transformation in adult is presented in this report.
  • Seven years ago, a 45 year-old male patient underwent biopsy to confirm pathologic characteristics and received craniocervical radiation and chemotherapy for a grade II astrocytoma in the cervical spinal cord.
  • The tumor at the cervical and brain lesions was classified as an astrocytoma (WHO grade II).
  • When a patient with low-grade astrocytoma in the spinal cord has new cranial symptoms after surgery, radiaton, and chemotherapy, the possibility of its metastasis should be suspected because it can spread to the intracranial cavity even without malignant transformation as shown in this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Dec;50(3):239-43 [11263503.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):374-7 [11437586.001]
  • [Cites] Spinal Cord. 2006 Dec;44(12):740-5 [16670687.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] Neurosurgery. 2005;56(1):191 [15617606.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):560-2 [9324344.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):141-51 [8971836.001]
  • [Cites] J Neurooncol. 1995;25(3):245-50 [8592175.001]
  • [Cites] J Neurosurg. 1995 Sep;83(3):480-5 [7666226.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] J Neurooncol. 1994;18(1):49-52 [8057134.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):355-9 [1506881.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Br J Surg. 1975 Feb;62(2):92-5 [1115920.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):114-8 [14762681.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):554-61 [12879473.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6 Suppl):508-14 [17184088.001]
  • (PMID = 19609424.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2711238
  • [Keywords] NOTNLM ; Astrocytoma / Cranial metastases / Intramedullary / Spinal cord tumor
  •  go-up   go-down


Advertisement
4. Khalatbari M, Borghei-Razavi H, Shayanfar N, Behzadi AH, Sepehrnia A: Collision tumor of meningioma and malignant astrocytoma. Pediatr Neurosurg; 2010;46(5):357-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of meningioma and malignant astrocytoma.
  • The pathology of tumors reported collision tumors composed of meningioma and malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389747.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Nano R, Capelli E, Facoetti A, Benericetti E: Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res; 2009 Jul;29(7):2461-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunobiological and experimental aspects of malignant astrocytoma.
  • Starting from 1992, the goal of our studies was to obtain new biological data on malignant astrocytomas to better understand the basic biology of the tumour and these are reviewed here.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596914.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2
  • [Number-of-references] 51
  •  go-up   go-down


6. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
  • PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas.
  • The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy.
  • PATIENTS AND METHODS: In a phase II trial, 60 patients with recurrent malignant astrocytomas were treated with bevacizumab and irinotecan.
  • Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%).
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • CONCLUSION: In this patient cohort, tumor expression levels of VEGF, the molecular target of bevacizumab, were associated with radiographic response, and the upstream promoter of angiogenesis, hypoxia, determined survival outcome, as measured from treatment initiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Hypoxia. Male. Middle Aged. Neovascularization, Pathologic. Proportional Hazards Models. Radiography. Retrospective Studies. Survival Analysis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down


7. Marsh J, Mukherjee P, Seyfried TN: Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab (Lond); 2008 Nov 25;5:33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet.
  • BACKGROUND: Astrocytomas are largely dependent on glycolysis to satisfy their bioenergetic requirements for growth and survival.
  • Therapies that target glycolysis can potentially manage astrocytoma growth and progression.
  • Dietary restriction of the high fat/low carbohydrate ketogenic diet (KD-R) reduces glycolysis and is effective in managing experimental mouse and human astrocytomas.
  • The goal here was to determine if low doses of 2-DG could act synergistically with the KD-R to better manage growth of the CT-2A malignant mouse astrocytoma.
  • METHODS: The therapeutic effect of a KD-R supplemented with a low dose of 2-DG (25 mg/kg) was examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown orthotopically.
  • Mice were fed the standard unrestricted diet for the first 3 days after tumor implantation prior to their separation into one of four diet groups fed either a standard rodent diet in unrestricted amounts (SD-UR) or a KD-R with or without 2-DG for 10 days.
  • 2-DG was initiated 6 days after tumor implantation and was continued for 7 days.
  • RESULTS: Energy intake, body weights, and CT-2A tumor weights were similar in the SD-UR and the SD-UR+2-2DG mouse groups over the dietary treatment period (days 3-13).
  • Tumor weights were about 48% and 80% lower in the KD-R and in the KD-R+2-DG groups, respectively, than in the SD-UR group.
  • CONCLUSION: Astrocytoma growth was reduced more in the KD-R mouse group supplemented with 2-DG than in the mouse groups receiving either dietary restriction or 2-DG alone, indicating a synergistic interaction between the drug and the diet.
  • The results suggest that management of malignant astrocytoma with restricted ketogenic diets could be enhanced when combined with drugs that inhibit glycolysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7751-62 [19047102.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Jan;28(1):1-16 [17684514.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Nutr Metab (Lond). 2007;4:5 [17313687.001]
  • [Cites] Epilepsia. 2007 Jan;48(1):31-42 [17241206.001]
  • [Cites] Behav Pharmacol. 2006 Sep;17(5-6):431-9 [16940764.001]
  • [Cites] Life Sci. 2006 Feb 16;78(12):1392-9 [16111712.001]
  • [Cites] Nutr Metab (Lond). 2005 Oct 21;2:30 [16242042.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):7023-30 [16061689.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):507-14 [16044218.001]
  • [Cites] Neurosci Lett. 2005 Sep 16;385(3):210-4 [15975714.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):615-7 [15687318.001]
  • [Cites] J Natl Cancer Inst. 1960 Feb;24:267-81 [14414406.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Natl Cancer Inst. 1958 Sep;21(3):485-94 [13576102.001]
  • [Cites] Arch Neurol. 1998 Jul;55(7):922-8 [9678309.001]
  • [Cites] J Am Coll Nutr. 1995 Apr;14(2):202-8 [7790697.001]
  • [Cites] Mol Chem Neuropathol. 1992 Oct;17(2):147-67 [1418222.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5794-6 [1394204.001]
  • [Cites] J Neurochem. 1991 Mar;56(3):1007-11 [1671582.001]
  • [Cites] J Nutr. 1984 Nov;114(11):2097-106 [6491763.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5622-9 [15328205.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19 [14769489.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1375-82 [14520474.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):529-37 [12859666.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3413-7 [12810678.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):805-12 [12232767.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1615-21 [12085212.001]
  • [Cites] J Lipid Res. 2008 Dec;49(12):2545-56 [18703489.001]
  • (PMID = 19032781.001).
  • [ISSN] 1743-7075
  • [Journal-full-title] Nutrition & metabolism
  • [ISO-abbreviation] Nutr Metab (Lond)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102135; United States / NINDS NIH HHS / NS / R01 NS055195; United States / NINDS NIH HHS / NS / R56 NS055195
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2607273
  •  go-up   go-down


8. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S: p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol; 2010 Oct;27(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 abnormality and tumor invasion in patients with malignant astrocytoma.
  • Malignant astrocytomas are characterized by diffusely infiltrating nature, and the abnormality of p53 is a cytogenetic hallmark of astrocytic tumors.
  • To elucidate the relationship between p53 abnormality and invasiveness of the tumors, we studied mutation and protein expression of p53 in 48 consecutive patients with malignant astrocytoma (14 anaplastic astrocytomas and 34 glioblastoma multiformes).
  • The tumors were classified into three categories according to the features of magnetic resonance imaging, and 5, 7, and 36 tumors were classified into diffuse, multiple, and single type, respectively.
  • We then examined how these tumor types correlate with MIB-1 staining index, TP53 gene mutation, and p53 protein expression.
  • Furthermore, diffuse- and multiple-type tumors were significantly correlated with poor progression-free survival, whereas only multiple-type tumors were significantly correlated with poor overall survival.
  • As diffuse and multiple features on imaging modalities represent invasive characteristics of the tumors, p53 abnormalities may affect the invasive and aggressive nature of malignant astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Genes, p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA, Neoplasm / genetics. Female. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Mutation / genetics. Mutation / physiology. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Survival Analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046311.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


9. Ryu HH, Jung S, Sun HS, Jung TY, Jin SG, Jin YH, Kim IY, Jeong YI, Kang SS: Screening for motility-associated genes in malignant astrocytoma cell lines. J Neurooncol; 2007 Apr;82(2):125-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for motility-associated genes in malignant astrocytoma cell lines.
  • The most characteristic feature of a malignant astrocytoma is its early and extensive infiltration into adjacent parenchymal structures.
  • We focused on detecting the possible expression changes as the determining factors for malignant astrocytoma's motile ability.
  • These findings suggest that the genes identified may be important for determining high motility in astrocytoma cell lines.
  • These findings may help us understand the molecular invasion mechanism in astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cell Movement. Gene Expression Profiling
  • [MeSH-minor] Humans. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048098.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C: Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci; 2008 Feb;15(2):114-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
  • Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma.
  • We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant / methods. Dendritic Cells / immunology. Immunotherapy, Active / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083572.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / Cancer Vaccines; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


11. Parafiniuk D, Jezewski D, Nowacki P: [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review]. Ann Acad Med Stetin; 2010;56(2):45-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review].
  • Astrocytomas--neroepithelial originated tumors that belong to the big, differential group of tumors, which derive from astrocytic glial.
  • They include slow growing tumors such as fibillary astrocytoma or very malignant glioblastoma multiforme.
  • The case which is being presented is of a forty nine year old woman operated in July 1997 because of a protoplasmic astrocytoma II WHO in the left frontal lobe.
  • Due to this adverse event MRI was ordered and suspicion of tumor recurrence was put forward.
  • Histopathology identified anaplastic astrocytoma III WHO.
  • According to literature, the factors regarding remission time, tumor malignancy and therapeutic aim were analyzed.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Astrocytoma. Female. Frontal Lobe. Humans. Reoperation. Seizures / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21473001.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down


12. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • We evaluated the addition of temozolomide (TMZ) to radiotherapy for newly diagnosed anaplastic gliomas in terms of tolerability, progression-free survival (PFS), and overall survival (OS).
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • Frequent mild toxicities were grade 1-2 nausea/vomiting (17 pts-63%), and grade 1-2 asthenia (8 pts-30%).
  • CONCLUSIONS: The addition of temozolomide to radiation therapy for newly diagnosed anaplastic gliomas is well tolerated and seems active; efficacy needs confirmation in a randomized clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M: Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.
  • : e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.
  • METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.
  • The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.
  • Out of 80 cycles received there was no anemia; 5 (6%) grade 1, 8 (10%) grade 2, 2 (3%) grade 3 leucopenia; 1 (1%) grade 1, 2 (3%) grade 2, 1 (1%) grade 3, 1 (1%) grade 4 thrombocytopenia; 9 (11%) grade 1, 7 (9%) grade 2, 32 (40%) grade 3, and 11 (14%) grade 4 lymphopenia.
  • Study was terminated in 2 patients (one with grade 4 thrombocytopenia and the other with grade 4 hepatic toxicity).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Rudnick JD, Phuphanich S, Chu R, Mazer M, Wang H, Serrano N, Francisco M, Black KL, Wheeler C, Yu J: A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
  • : 2033 Background: Our prior immunotherapy trials demonstrated efficacy in generating a tumor specific immune response in malignant glioma and the potential for high tumor-specific toxicity and sustained tumoricidal activity.
  • METHODS: We exploited this synergistic effect to maintain a cytotoxic environment around the tumor milieu.
  • Patients with high-grade glioma were eligible after maximal resection with biodegradable carmustine (BCNU) wafer placement.
  • Screening leukapheresis is used to isolate mononuclear cells which are differentiated into dendritic cells, pulsed with tumor lysate, and then 3 intradermal vaccines are administered at 2-week intervals.
  • The histology included 3 newly diagnosed glioblastoma multiforme (GBM), 8 recurrent GBM, 2 newly diagnosed anaplastic astrocytoma (AA), and 2 recurrent AA.
  • Our preliminary data on 15 patients and 39 courses of Dendritic Cell vaccines demonstrate one grade 3 toxicity of fever/chest pain.
  • CONCLUSIONS: This phase I study demonstrates the safety, feasibility of dendritic cell vaccination with biodegradable carmustine (BCNU) wafers with one grade 3 AE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964627.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Herndon J 2nd, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS: Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.
  • : e13016 Background: Recurrent malignant gliomas have a poor prognosis, with a median survival of 6-15 months, with grade 4 glioblastomas more aggressive than grade 3 anaplastic astrocytomas or oligodendrogliomas.
  • We report a phase I trial of vandetanib in combination with oral etoposide for recurrent malignant glioma.
  • METHODS: Patients with histologically documented recurrent grade 3 or grade 4 malignant glioma were eligible.
  • There was more hematologic toxicity than expected, with 3/6 of the patients enrolled at dose level 1 developing grade 4 neutropenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962830.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  • METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.
  • Dose-limiting toxicities were: deep venous thrombosis (1 grade 3); nausea and vomiting (1 grade 3); diarrhea (1 grade 3); elevated ALT (1 grade 3); elevated creatinine (1 grade 3); and fatigue (1 grade 3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S: The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):2057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab.
  • Histologies included glioblastoma (GB), anaplastic astrocytomas (AA), anaplastic oligodendrogliomas (AO), anaplastic oligoastrocytomas (AOA), and low-grade astrocytomas.
  • It is unclear why the disparity among this subset of patients occurs, however, we hypothesize that this may once again highlight the distinct tumor biology among young glioma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Franceschi E, Tosoni A, Ermani M, Spagnolli F, La Torre L, Galzio RJ, Pozzati E, Talacchi A, Benevento F, Brandes AA: Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas.
  • : e13003 Background: Chromosomes 1p/19q codeletion has been recognized as a prognostic and predictive factor in patients (pts) with grade 3 gliomas.
  • Non-codeleted (intact) anaplastic oligodendroglioma showed a survival comparable to that usually observed in pts with anaplastic astrocytomas; MGMT methylation status, moreover, has been found to be a prognostic factor in glioblastoma and anaplastic gliomas (AG).
  • Histology was anaplastic oligodendroglioma in 17 pts, anaplastic oligoastrocytoma in 20 pts, and anaplastic astrocytoma in 30 pts; all these pts were 1p19q intact and received surgery, RT, and CT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tosoni A, Franceschi E, Ermani M, Bacci A, Volpin L, Lombardo L, Ravenna G, Pinna G, Poggi R, Brandes AA: MGMT methylation status as a prognostic factor in anaplastic astrocytomas. J Clin Oncol; 2009 May 20;27(15_suppl):2052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT methylation status as a prognostic factor in anaplastic astrocytomas.
  • However, further data on the epigenetic feature are needed before its role in rare diseases such as anaplastic astrocytomas (AA) can be established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964674.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM: Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):2042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.
  • Safety and efficacy of intracerebral inoculations of G207 to patients suffering from recurrent malignant gliomas have been demonstrated in previous clinical trials.
  • METHODS: In this phase I clinical trial, a total of 1 x 10<sup>9</sup> plaque forming units (pfu) G207 were administered by five stereotactic injections of 0.2 mL each into regions of recurrent malignant glioma defined by MRI, followed by focal radiation therapy 24 hours post injection.
  • Included patients suffered from inoperable pathologically proven recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) which was progressive despite radiotherapy or chemotherapy and failed external beam radiotherapy > 5 Gray prior to study enrolment.
  • The 2 patients with initial PR (1xGBM, 1xAA) were re-treated with G207/Irradiation at time point of tumor recurrence, showing PR one month after re-treatment again.
  • Within persistent areas of tumor, HSV staining was present by using a polyclonal antibody for HSV, indicating intratumoral G207 replication (proof of concept).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K: Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res; 2008 Sep;14(3):293-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.
  • The aim of the study was to analyze the expression of OPN in human astrocytomas and to correlate it with angiogenesis and patients' outcome.
  • Seventy-six human astrocytomas including eight pilocytic astrocytomas (grade I), 10 diffuse astrocytomas (grade II), 8 anaplastic astrocytomas (grade III) and 50 glioblastomas (grade IV) were immunohistochemically stained for OPN protein.
  • Astrocytomas were heterogeneous regarding the OPN expression.
  • Our results indicate the overexpression of OPN protein in astrocytoma cells and suggest the role of OPN in astrocytoma progression and angiogenesis.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Brain Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Osteopontin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493866.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


22. Reardon DA, Rich JN, Friedman HS, Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol; 2006 Mar 10;24(8):1253-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of malignant astrocytoma.
  • Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms.
  • Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress.
  • The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.
  • [MeSH-major] Astrocytoma / therapy. Central Nervous System Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 209
  •  go-up   go-down


23. Llaguno SA, Chen J, Kwon CH, Parada LF: Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. Cold Spring Harb Symp Quant Biol; 2008;73:421-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma.
  • Malignant astrocytomas are highly invasive brain tumors that portend poor prognosis and dismal survival.
  • We previously reported tumor suppressor mouse models based on conditional inactivation of human astrocytoma-relevant genes p53, Nf1, and Pten.
  • These mice develop, with full penetrance, varying grades of astrocytic malignancy that recapitulate the human condition histologically and molecularly.
  • Our studies indicate a central role for neural stem cells and stem-cell-like cancer cells in tumor initiation and progression.
  • These mouse models thus represent powerful tools for investigating various aspects of tumor development that otherwise cannot be explored in humans.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology. Neurons / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Genes, Tumor Suppressor. Humans. Mice. Models, Neurological. Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022744.001).
  • [ISSN] 1943-4456
  • [Journal-full-title] Cold Spring Harbor symposia on quantitative biology
  • [ISO-abbreviation] Cold Spring Harb. Symp. Quant. Biol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P50NS05260602
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


24. Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem; 2005 Aug;53(8):997-1002
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does vasculogenic mimicry exist in astrocytoma?
  • Vasculogenic mimicry (VM) has been observed in melanoma and in some nonmelanoma tumor types.
  • It is unknown whether a similar VM phenomenon exists in astrocytoma.
  • The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.
  • The results demonstrated that endothelium-lined vessels dominated the tumor microvasculature and stained positively for PAS, laminin, and endothelial marker.
  • PAS-positive pattern of VM was found in two grade IV astrocytomas.
  • Channels stained positively for PAS, laminin, and negatively for CD34 of the VM entrapped in the tumor tissue.
  • Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.
  • It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.
  • The present results suggest that VM phenomenon exists in some malignant astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers / metabolism. Coloring Agents. Endothelium, Vascular / metabolism. Humans. Microcirculation. Neoplasm Staging. Periodic Acid. Schiff Bases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923371.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid
  •  go-up   go-down


25. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell; 2005 Aug;8(2):119-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
  • Malignant astrocytoma, the most prevalent primary brain tumor, is resistant to all known therapies and frequently harbors mutations that inactivate p53 and activate Ras signaling.
  • We have generated mouse strains that lack p53 and harbor a conditional allele of the NF1 tumor suppressor that negatively regulates Ras signaling.
  • The mice develop malignant astrocytomas with complete penetrance.
  • The majority of tumors display characteristics of glioblastoma multiforme with concomitant alteration of signaling pathways previously described in the human counterparts of this neoplasm.
  • We find that the sequence of tumor suppressor inactivation influences tumorigenicity and that earliest evidence of tumor formation localizes to regions of the brain that contain a multipotent stem cell population capable of in vivo differentiation into neurons and glia.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2121-7 [8668337.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Microsc Res Tech. 1998 Jun 1;41(5):344-58 [9672418.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Curr Opin Neurobiol. 1999 Feb;9(1):135-41 [10072370.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17528-32 [15574494.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Neuron. 2000 Feb;25(2):317-29 [10719888.001]
  • [Cites] Neuron. 2000 Feb;25(2):331-43 [10719889.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):19-28 [11237520.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Cereb Cortex. 2003 Jun;13(6):580-7 [12764031.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4305-9 [12907595.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Curr Opin Neurobiol. 2002 Jun;12(3):244-9 [12049929.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):157-68 [12086874.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):11-9 [12461769.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13008-13 [15319471.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):3910-8 [2454731.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2987-90 [1349850.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Jan;52(1):31-8 [8381161.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1324-30 [8118823.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 6;86(13):1011-7 [8007011.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):613-24 [11300931.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3826-36 [11325859.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • (PMID = 16098465.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS034296-07; United States / NINDS NIH HHS / NS / NS034296-07; United States / NCI NIH HHS / CA / P20 CA086354; United States / NINDS NIH HHS / NS / R01 NS034296-06; United States / NINDS NIH HHS / NS / R01 NS034296; United States / NINDS NIH HHS / NS / NS034296-06; United States / NCI NIH HHS / CA / P20 CA86354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS263629; NLM/ PMC3024718
  •  go-up   go-down


26. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J: Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol; 2007;377:203-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis.
  • Astrocytoma is graded as pilocytic (WHO grade I), diffuse (WHO grade II), anaplastic (WHO grade III), and glioblastoma multiforme (WHO grade IV).
  • The progression from low- to high-grade astrocytoma is associated with distinct molecular changes that vary with patient age, yet the prognosis of high-grade tumors in children and adults is equally dismal.
  • Whether specific gene expression changes are consistently associated with all high-grade astrocytomas, independent of patient age, is not known.
  • To address this question, we reanalyzed the microarray datasets comprising astrocytomas from children and adults, respectively.
  • We identified nine genes consistently dysregulated in high-grade tumors, using four novel tests for identifying differentially expressed genes.
  • Four genes encoding ribosomal proteins (RPS2, RPS8, RPS18, RPL37A) were upregulated, and five genes (APOD, SORL1, SPOCK2, PRSS11, ID3) were downregulated in high-grade by all tests.
  • Expression results were validated using a third astrocytoma dataset.
  • APOD, the most differentially expressed gene, has been shown to inhibit tumor cell and vascular smooth muscle cell proliferation.
  • This suggests that dysregulation of APOD may be critical for malignant astrocytoma formation, and thus a possible novel universal target for therapeutic intervention.
  • Further investigation is needed to evaluate the role of APOD, as well as the other genes identified, in malignant astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adult. Child. Chromosomes, Human. Cluster Analysis. Data Interpretation, Statistical. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Models, Genetic. Neoplasm Recurrence, Local. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634619.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 49
  •  go-up   go-down


27. Nagai S, Kurimoto M, Washiyama K, Hirashima Y, Kumanishi T, Endo S: Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol; 2005 Sep;74(2):105-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines.
  • In malignant astrocytoma cells, it was reported that NF-kappaB was activated aberrantly and promoted their proliferation.
  • Thus, inhibition of NF-kappaB activity is considered to be a promising therapeutic strategy for malignant astrocytoma.
  • In this study, we investigated inhibitory effects of curcumin on NF-kappaB activity and cellular proliferation, and induction of apoptosis by curcumin in human malignant astrocytoma cell lines.
  • Alteration of NF-kappaB activity in NP-2 human malignant astrocytoma cell line after treatment with curcumin was examined using electrophoretic mobility shift assay.
  • Alterations of DNA synthesis and cellular growth in five human malignant astrocytoma cell lines after treatment with curcumin were examined using [(3)H]thymidine incorporation assay and the trypan blue dye exclusion method, respectively.
  • Induction of apoptosis by curcumin in NP-2 and NP-3 human malignant astrocytoma cell lines was examined by DNA-fragmentation analysis and morphological observation.
  • The DNA synthesis and the cellular growth were inhibited by curcumin in dose-dependent manner in all the five malignant astrocytoma cell lines.
  • These results indicate that curcumin inhibits the cellular proliferation and induces apoptosis in human malignant astrocytoma cell lines.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Astrocytoma / drug therapy. Cell Proliferation / drug effects. Curcumin / therapeutic use. NF-kappa B / drug effects
  • [MeSH-minor] Electrophoretic Mobility Shift Assay. Humans. Thymidine / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193380.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; IT942ZTH98 / Curcumin; VC2W18DGKR / Thymidine
  •  go-up   go-down


28. Miura FK, Alves MJ, Rocha MC, da Silva R, Oba-Shinjo SM, Marie SK: Xenograft transplantation of human malignant astrocytoma cells into immunodeficient rats: an experimental model of glioblastoma. Clinics (Sao Paulo); 2010 Mar;65(3):305-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xenograft transplantation of human malignant astrocytoma cells into immunodeficient rats: an experimental model of glioblastoma.
  • INTRODUCTION: Astrocytic gliomas are the most common intracranial central nervous system neoplasias, accounting for about 60% of all primary central nervous system tumors.
  • OBJECTIVE: To develop an experimental malignant astrocytoma model with the characteristics of the human tumor.
  • METHOD: Primary cells from subcutaneous xenograft tumors produced with malignant astrocytoma U87MG cells were inoculated intracerebrally by stereotaxis into immunosuppressed (athymic) Rowett rats.
  • CONCLUSION: A malignant astrocytoma intracerebral xenograft model with poorly invasive behavior was achieved in athymic Rowett rats.
  • Tumor invasiveness in an experimental animal model may depend on a combination of several factors, including the cell line used to induce tumor formation, the rat strains and the status of the animal's immune system.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Immunocompromised Host
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Female. Humans. Neoplasm Transplantation. Rats. Rats, Nude. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2887-900 [16886610.001]
  • [Cites] Surg Neurol. 2005 Jun;63(6):511-9; discussion 519 [15936366.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Arq Neuropsiquiatr. 2008 Jun;66(2A):238-41 [18545790.001]
  • [Cites] J Neurooncol. 2001 May;52(3):205-15 [11519850.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2A):234-40 [12806502.001]
  • [Cites] J Neurol. 1981;224(3):183-92 [6162014.001]
  • [Cites] Funct Dev Morphol. 1993;3(3):175-80 [8167397.001]
  • [Cites] J Neurosurg. 1994 May;80(5):865-76 [8169627.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):59-67 [10360479.001]
  • [Cites] Exp Neurol. 2004 Dec;190(2):478-85 [15530886.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]
  • (PMID = 20360922.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC2845772
  • [Keywords] NOTNLM ; Athymic Rowett rats / Brain tumor / Experimental model / U87MG cells
  •  go-up   go-down


29. Li B, Qi XQ, Chen X, Huang X, Liu GY, Chen HR, Huang CG, Luo C, Lu YC: Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res; 2010 Sep 17;1352:200-7
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma.
  • However, the contribution of TPX2 expression to astrocytoma progression is unclear.
  • The aim of this study was to investigate TPX2 expression in human astrocytoma samples and cell lines.
  • TPX2 protein expression was detected in the nucleus of astrocytoma tissues by immunohistochemistry and immunofluorescence staining.
  • Real-time PCR and Western blot analysis showed that the expression levels of TPX2 were higher in high-grade astrocytoma tissues and cell lines than that in low-grade astrocytoma tissues and normal cell lines.
  • Immunohistochemical analysis of tumor tissues from 52 patients with astrocytoma showed that TPX2 over-expression was significantly associated with decreased patient survival.
  • These data suggest that TPX2 expression is associated with the progression of malignant astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Cell Cycle Proteins / genetics. Microtubule-Associated Proteins / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Apoptosis. Aurora Kinases. Brain / metabolism. Cell Division. Cell Line, Tumor. Cyclin B1 / genetics. Cyclin D1 / genetics. Disease Progression. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Protein-Serine-Threonine Kinases / genetics. Proto-Oncogene Proteins c-myc / genetics. Survival Rate. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20599806.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin B1; 0 / Microtubule-Associated Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / TPX2 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


30. Kojadinovic Z, Papic V, Cigic T, Vulekovic P, Popovic Lj, Jajic Dj: A new scoring system for malignant astrocytomas. Zentralbl Neurochir; 2008 May;69(2):65-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new scoring system for malignant astrocytomas.
  • BACKGROUND: Currently there are a few scoring systems for malignant astrocytoma, but they are not widely accepted.
  • The aim of this study was to create a scoring system for supratentorial malignant astrocytoma, which could be used in both developed and developing societies.
  • METHODS: This study was performed in 128 patients who had supratentorial malignant astrocytoma (grade III or IV).
  • By using the most appropriate four parameters (age, KPS, initial seizure and histopathological grade) we created a scoring system - MAS (Malignant Astrocytoma Score).
  • CONCLUSIONS: We are of the opinion that MAS represents a useful scoring system to determine the severity of the illness and make a prognosis for both individuals and groups of patients with malignant supratentorial astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures / mortality. Prognosis. Proportional Hazards Models. ROC Curve. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444219.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Ward SJ, Karakoula K, Phipps KP, Harkness W, Hayward R, Thompson D, Jacques TS, Harding B, Darling JL, Thomas DG, Warr TJ: Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation. J Neurooncol; 2010 Jul;98(3):305-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation.
  • Little is known about the cytogenetic and molecular genetic events that lead to the formation of paediatric astrocytoma.
  • We have analysed 57 paediatric astrocytoma (WHO grades I-IV) using comparative genomic hybridisation in order to identify common regions of abnormality.
  • The presence of copy number alterations was significantly associated with increasing grade of malignancy, and gain of 12q and the presence of high-copy number amplification were associated with a poor outcome in patients with malignant astrocytoma (P = 0.0039 and 0.0085, respectively).
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Comparative Genomic Hybridization / methods. In Situ Hybridization, Fluorescence / methods


32. Kawarabuki K, Ohta T, Hashimoto N, Wada K, Maruno M, Yamaki T, Ueda S: Cerebellar glioblastoma genetically defined as a secondary one. Clin Neuropathol; 2005 Mar-Apr;24(2):64-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present case, tumor lesions were observed in each cerebellar hemisphere.
  • The left-side lesion was diagnosed as glioblastoma, and the right-side lesion as malignant astrocytoma by histopathology.
  • Immunohistochemistry revealed that the tumor cells of the left-side lesion was positive for p53, whereas epidermal growth factor receptors (EGFR) were negative in tumor cells from both sides.
  • Genetic alterations were investigated using a genome DNA microarray (GenoSensor Array 300), which has led us to define this tumor as a secondary glioblastoma.

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803805.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Wu-Chen WY, Jacobs DA, Volpe NJ, Dalmau JO, Moster ML: Intracranial malignancies occurring more than 20 years after radiation therapy for pituitary adenoma. J Neuroophthalmol; 2009 Dec;29(4):289-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging disclosed a left parasellar mass and a midbrain/pontine signal abnormality.
  • Biopsy of the parasellar mass revealed a malignant sarcoma.
  • The brainstem abnormality was presumptively diagnosed as a malignant glioma.
  • A 63-year-old man developed a malignant astrocytoma of the left optic nerve and chiasm 23 years after partial excision and radiation of a nonsecreting pituitary adenoma.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952902.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Bozinov O, Köhler S, Samans B, Benes L, Miller D, Ritter M, Sure U, Bertalanffy H: Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev; 2008 Jan;31(1):83-9; discussion 89-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate genes for the progression of malignant gliomas identified by microarray analysis.
  • Malignant astrocytomas of World Health Organization (WHO) grade III or IV have a reduced median survival time, and possible pathways have been described for the progression of anaplastic astrocytomas and glioblastomas, but the molecular basis of malignant astrocytoma progression is still poorly understood.
  • We compared the transcriptional profile of 4,608 genes in tumours of 15 patients including 6 anaplastic astrocytomas (WHO grade III) and 9 glioblastomas (WHO grade IV) using microarray analysis.
  • We identified 166 gene alterations with a fold change of 2 and higher whose mRNA levels differed (absolute value of the t statistic of 1.96) between the two malignant glioma groups.
  • Further analyses confirmed same transcription directions for Olig2 and IL-13Ralpha2 in anaplastic astrocytomas as compared to glioblastomas.
  • IL-13Ralpha2 and Olig2 have been identified and confirmed to be interesting candidate genes whose differential expression likely plays a role in malignant progression of astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Expression Profiling. Glioblastoma / genetics. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neurosurg Rev. 2008 Apr;31(2):247-8
  • (PMID = 17917751.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


35. Roselli F, Pisciotta NM, Aniello MS, Niccoli-Asabella A, Defazio G, Livrea P, Rubini G: Brain F-18 Fluorocholine PET/CT for the assessment of optic pathway glioma in neurofibromatosis-1. Clin Nucl Med; 2010 Oct;35(10):838-9
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging, magnetic resonance spectroscopy (MRS), and F-18 fluorocholine revealed a splenial mass with imaging features compatible with malignant astrocytoma.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Optic pathway glioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838306.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / fluorocholine; N91BDP6H0X / Choline
  •  go-up   go-down


36. Kikuchi T: [Novel immunotherapeutic approach]. Gan To Kagaku Ryoho; 2005 Apr;32(4):453-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant astrocytoma is the most common primary brain tumor in adults.
  • The median survival time of patients with high-grade malignant astrocytoma is about 1 year, despite aggressive treatment with surgical resection, radiotherapy, and cytotoxic chemotherapy.
  • The author reviews immunotherapeutic approaches for malignant gliomas and the relevance of recent clinical trials and their outcomes.
  • DCs have been investigated in several clinical trials in patients with malignant tumors including malignant gliomas.
  • So far, seven papers concerning immunotherapy with DCs against malignant gliomas have been published.
  • These reports demonstrate that immunotherapy with DCs induces immune responses and clinically antitumor effects in some patients with malignant glioma.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Glioma / therapy. Immunotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853209.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunotoxins; 0 / Interleukin-13; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 23
  •  go-up   go-down


37. Gathinji M, McGirt MJ, Attenello FJ, Chaichana KL, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A: Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol; 2009 Mar;71(3):299-303, discussion 303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of preoperative depression and survival after resection of malignant brain astrocytoma.
  • It remains unclear if clinical depression affects survival after surgical management of malignant brain astrocytoma.
  • METHODS: One thousand fifty-two patients undergoing surgical management for malignant brain astrocytoma (WHO grade 3 or 4) performed at a single institution from 1995 to 2006 were retrospectively reviewed.
  • Pathology was WHO grade IV in 829 (79%) and grade III in 223 (21%).
  • Adjusting for all variables associated with survival in this model, age (P < .001), KPS (P < .001), WHO grade III vs IV (P < .001), primary versus secondary resection (P < .001), gross-total resection (P < .001), Gliadel wafer implantation (P = .048), postoperative temozolomide therapy (P < .001), and subsequent resection at time of recurrence (P < .001); preoperative depression was independently associated with decreased survival (relative risk [95% CI]: 1.41 [1.1-1.96], P < .05).
  • CONCLUSION: In our experience, patients who are actively depressed at the time of surgery were associated with decreased survival after surgical management of malignant astrocytoma, independent of degree of disability, tumor grade, or subsequent treatment modalities.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality. Depression / mortality

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786716.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Lin C, Ma L, Yin J, Chen J: [A medical image semantic modeling based on hierarchical Bayesian networks]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Apr;26(2):400-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As for the validity of this method, we have built a multi-level semantic model from a small set of astrocytoma MRI (magnetic resonance imaging) samples, in order to extract semantics of astrocytoma in malignant degree.
  • [MeSH-minor] Artificial Intelligence. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Humans. Image Interpretation, Computer-Assisted / methods. Semantics

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499811.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


39. Nagatani M, Ando R, Yamakawa S, Saito T, Tamura K: Histological and immunohistochemical studies on spontaneous rat astrocytomas and malignant reticulosis. Toxicol Pathol; 2009 Aug;37(5):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical studies on spontaneous rat astrocytomas and malignant reticulosis.
  • Among spontaneous neoplasms of the rat central nervous system, the discrimination between astrocytoma and malignant reticulosis (MR) is sometimes difficult because of their similar cell morphology and infiltration patterns.
  • These cases were diagnosed as benign/malignant astrocytoma containing no neoplastic oligodendroglial elements or MR according to the diagnostic criteria of the World Health Organization International Classification of Rodent Tumors (Mohr et al. 1994).
  • Astrocytomas were divided into three types and MR into two types based on the number of lesions, cellularity and infiltration patterns, and so on.
  • None of the tumor types showed any reactivity for GFAP or S-100 protein.
  • From the results of morphological and immunohistochemical examinations, it was indicated that there are no distinctive differences between spontaneous astrocytomas and MR in rats, and they are probably derived from the same cell lineage, that is, microglia, macrophage, or radial glia.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Central Nervous System Neoplasms / metabolism. Central Nervous System Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487256.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Vimentin
  •  go-up   go-down


40. Ehling R, Sterlacci W, Maier H, Berger T: A 45-year old male with left-sided hemihypesthesia. Brain Pathol; 2010 Mar;20(2):515-8
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extensive immunological and radiological investigations were not able to differentiate between an intrinsic brain tumor and a demyelinating disease.
  • Stereotactic biopsies of the brainstem were performed; the findings of abundant Rosenthal fibers, interjacent spindle-shaped and gemistocytic cells partially with dark and irregularly formed nuclei favored primarily the diagnosis of a malignant astrocytoma, although a demyelinating disease could not be definitely excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438473.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Jang FF, Wei W, De WM: Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma. J Ayub Med Coll Abbottabad; 2008 Apr-Jun;20(2):105-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
  • BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema.
  • METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
  • RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
  • CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.
  • [MeSH-major] Astrocytoma / blood supply. Brain Edema / etiology. Brain Neoplasms / blood supply. Fibroblast Growth Factor 2 / biosynthesis. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385471.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


42. Ido K, Nakagawa T, Sakuma T, Takeuchi H, Sato K, Kubota T: Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology; 2008 Dec;28(6):604-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors.
  • High-grade astrocytic tumors, such as glioblastoma, possess rich vascular components, which are necessary for their growth.
  • VEGF-A is considered to be the major mediator of angiogenesis in malignant neoplasms including high-grade astrocytic tumors.
  • The upregulation of VEGF-A expression in tumor cells is induced by two mechanisms: the transcriptional activation and the post-transcriptional stabilization of VEGF-A mRNA.
  • While the former mechanism mediated by hypoxia inducible factor-1 alpha (HIF-1alpha) has been revealed, the latter mediated by mRNA stability factor HuR remains unclear in astrocytic tumors.
  • In the present study, we investigated the expression of VEGF-A and mRNA stability factor HuR in supratentorial astrocytic tumors of 27 adults using RT-PCR, ELISA, and immunohistochemistry.
  • Furthermore, we studied the involvement of HuR in the upregulation of VEGF-A expression using malignant astrocytoma cell lines.
  • In higher-grade astrocytic tumors, the level of VEGF-A and microvascular density were elevated, cytoplasmic expression of HuR, which potentially means the protection of VEGF-A mRNA from degradation by ribonucleases, appeared, and they were correlated positively.
  • In in vitro experiments, the inhibition of the cytoplasmic translocation of HuR protein by leptomycin B (LMB) reduced the upregulation of VEGF-A expression in malignant astrocytic tumor cells under hypoxic conditions.
  • These findings suggest that the expression of VEGF-A and cytoplasmic translocation of HuR relates to the histological grade, and that HuR is involved in the upregulation of VEGF-A expression, in human astrocytic tumors.
  • [MeSH-major] Antigens, Surface / metabolism. Astrocytoma / metabolism. RNA-Binding Proteins / metabolism. Supratentorial Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiogenesis Inducing Agents. Cytoplasm / metabolism. ELAV Proteins. ELAV-Like Protein 1. Enzyme-Linked Immunosorbent Assay. Fatty Acids, Unsaturated / pharmacology. Female. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged. RNA Processing, Post-Transcriptional. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498284.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Fatty Acids, Unsaturated; 0 / RNA-Binding Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 87081-35-4 / leptomycin B
  •  go-up   go-down


43. Nagatani M, Yamakawa S, Ando R, Edamoto H, Saito T, Tamura K: Highly invasive intracranial malignant schwannoma in a rat. J Toxicol Pathol; 2009 Jun;22(2):139-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly invasive intracranial malignant schwannoma in a rat.
  • A highly invasive intracranial malignant schwannoma containing several masses was detected in a 28-week-old male Crl:CD(SD) rat.
  • The tumor cells invaded not only the brain but also the parietal bone.
  • In the brain, the tumor cells infiltrated diffusely into the leptomeningeal and perivascular spaces and parenchyma, in which the tumor cell morphology and invasive pattern closely resembled those of malignant astrocytoma and malignant reticulosis.
  • Immunohistochemically, the tumor cells in the masses showed positive reactions for both S-100 protein and GFAP, while those in the cerebral invasion sites were negative for GFAP and less positive for S-100 protein.
  • Electron microscopically, a single basal lamina layer and short intricate cell processes were confirmed in the tumor cells.
  • From these results, the present tumor was diagnosed as a malignant schwannoma arising in the cranial cavity, probably originating from the trigeminal nerve.
  • The present tumor is considered to be a relatively unique malignant schwannoma based on its growth and invasion patterns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22271987.001).
  • [ISSN] 0914-9198
  • [Journal-full-title] Journal of toxicologic pathology
  • [ISO-abbreviation] J Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3246059
  • [Keywords] NOTNLM ; cranial cavity / malignant schwannoma / rat / spontaneous
  •  go-up   go-down


44. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene.
  • Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS).
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


45. Widmer M, Hanemann CO, Zajicek J: High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. J Neurosci Res; 2008 Nov 1;86(14):3212-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioma cells (astrocyte-derived brain tumor cells) express cannabinoid receptors, and numerous in vitro and in vivo studies performed in rodents have concluded that apoptosis could be induced by cannabinoids in these cells.
  • Whether this also applies to human cells is controversial; we, therefore, assessed the effect of cannabinoids on human glioma cell viability with the human astrocytoma cell line U373MG.
  • Human U373MG glioma cells are sensitive only to very high, pharmacologically irrelevant concentrations of cannabinoids, so it seems unlikely that cannabinoids would constitute promising molecules for treating malignant astrocytoma; they do not induce glioma cell death at doses that could be applied safely to humans.
  • [MeSH-minor] Blotting, Western. Brain Neoplasms / metabolism. Cannabinoid Receptor Agonists. Cell Line, Tumor. Cell Proliferation / drug effects. Fluorescent Antibody Technique. Humans. Receptors, Cannabinoid / drug effects. Signal Transduction / drug effects. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. delta 9-Tetrahydrocannabinol .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18615640.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cannabinoid Receptor Agonists; 0 / Receptors, Cannabinoid; 7J8897W37S / Dronabinol
  •  go-up   go-down


46. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H: Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol; 2008 Oct;15(10):2887-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
  • BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival.
  • We set out to characterize Gliadel-associated morbidity in our 10-year experience with Gliadel wafers for treatment of malignant glioma.
  • METHODS: We retrospectively reviewed records of 1013 patients undergoing craniotomy for resection of malignant brain astrocytoma (World Health Organization grade III/IV disease).
  • RESULTS: A total of 1013 craniotomies were performed for malignant brain astrocytoma.
  • A total of 288 (28%) received Gliadel wafer (250 glioblastoma multiforme (GBM), 38 anaplastic astrocytoma/anaplastic oligodendroglioma (AA/AO), 166 primary resection, 122 revision resection).
  • Patients in Gliadel versus non-Gliadel cohorts had similar incidences of perioperative surgical site infection (2.8% vs. 1.8%, P = .33), cerebrospinal fluid leak (2.8% vs. 1.8%, P = .33), meninigitis (.3% vs. .3%, P = 1.00), incisional wound healing difficulty (.7% vs. .4%, P = .63), symptomatic malignant edema (2.1% vs. 2.3%, P = 1.00), 3-month seizure incidence (14.6% vs. 15.7%, P = .65), deep-vein thrombosis (6.3% vs. 5.2%, P = .53), and pulmonary embolism (PE) (4.9% vs. 3.7%, P = .41).
  • CONCLUSION: In our experience, use of Gliadel wafer was not associated with an increase in perioperative morbidity after surgical treatment of malignant astrocytoma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636295.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biocompatible Materials; 0 / Decanoic Acids; 0 / Drug Carriers; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


47. Bucci B, Misiti S, Cannizzaro A, Marchese R, Raza GH, Miceli R, Stigliano A, Amendola D, Monti O, Biancolella M, Amati F, Novelli G, Vecchione A, Brunetti E, De Paula U: Fractionated ionizing radiation exposure induces apoptosis through caspase-3 activation and reactive oxygen species generation. Anticancer Res; 2006 Nov-Dec;26(6B):4549-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, post-operative RT is considered the standard treatment adjuvant to surgery since its ability to prolong median survival of patients with malignant astrocytoma has been shown; nevertheless the ionizing radiation (IR) treatment fails in a considerable number of astrocytoma patients.
  • MATERIALS AND METHODS: Using an ADF human astrocytoma cell line the molecular mechanisms involved in the DNA damage induced by fractionated irradiation (FIR) and single IR treatment have been investigated.
  • RESULTS: FIR and single IR treatment inhibited the growth of the ADF human astrocytoma cell line.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Caspase 3 / metabolism. Radiation, Ionizing. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Apoptosis. Blotting, Western. Cell Line, Tumor. Dose Fractionation. Enzyme Activation. Humans. Oligonucleotide Array Sequence Analysis


48. Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL: Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer; 2008 Feb 15;122(4):807-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas.
  • We have performed cDNA microarray analyses to identify gene expression differences between highly invasive glioblastoma multiforme (GBM) and typically benign pilocytic astrocytomas (PA).
  • Despite the significant clinical and pathological differences between the 2 tumor types, only 63 genes were found to exhibit 2-fold or greater overexpression in GBM as compared to PA.
  • In the examination of more than 100 tumors of the central nervous system, we found progressively higher expression of MELK with astrocytoma grade and a noteworthy uniformity of high level expression in GBM.
  • We found neither gene promoter hypomethylation nor amplification to be a factor in MELK expression, but were able to demonstrate that MELK knockdown in malignant astrocytoma cell lines caused a reduction in proliferation and anchorage-independent growth in in vitro assays.
  • Among them, MELK correlated with malignancy grade in astrocytomas and represents a therapeutic target for the management of the most frequent brain tumors in adult and children.
  • [MeSH-major] Astrocytoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Apoptosis. Brain / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cell Proliferation. Child. DNA Methylation. Gene Dosage. Humans. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960622.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / MELK protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


49. Pavon LF, Marti LC, Sibov TT, Malheiros SM, Oliveira DM, Guilhen DD, Camargo-Mathias MI, Amaro Junior E, Gamarra LF: The ultrastructural study of tumorigenic cells using nanobiomarkers. Cancer Biother Radiopharm; 2010 Jun;25(3):289-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent advances, patients with malignant brain tumors still have a poor prognosis.
  • Glioblastoma (WHO grade 4 astrocytoma), the most malignant brain tumor, represents 50% of all astrocytomas, with a median survival rate of <1 year.
  • The process of tumor cell labeling using nanoparticles can successfully contribute to the identification of tumorigenic cells and consequently for better understanding of glioblastoma genesis and recurrence.
  • In addition, this method may help further studies in tumor imaging, diagnosis, and prognostic markers detection.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / metabolism. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, CD29 / immunology. Antigens, CD29 / metabolism. Antigens, CD44 / immunology. Antigens, CD44 / metabolism. Biomarkers / analysis. Biomarkers / chemistry. Cell Line, Tumor. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Cytoplasmic Vesicles / metabolism. Endocytosis / immunology. Flow Cytometry. Forkhead Transcription Factors / chemistry. Forkhead Transcription Factors / metabolism. Glycoproteins / immunology. Glycoproteins / metabolism. Humans. Immunophenotyping. Magnetite Nanoparticles / chemistry. Microscopy, Electron, Transmission. Nanomedicine / methods. Peptides / immunology. Peptides / metabolism. Quantum Dots. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578834.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD29; 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44 protein, human; 0 / ENG protein, human; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Glycoproteins; 0 / Magnetite Nanoparticles; 0 / Peptides; 0 / Receptors, Cell Surface
  •  go-up   go-down


50. Laczko R, Szauter KM, Jansen MK, Hollosi P, Muranyi M, Molnar J, Fong KS, Hinek A, Csiszar K: Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes. Neuropathol Appl Neurobiol; 2007 Dec;33(6):631-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have recently reported the ECM enzyme, lysyl oxidase (LOX), in the central nervous system and observed up-regulation of LOX in anaplastic astrocytoma cells.
  • In this study, we tested the hypothesis that active LOX is expressed in anaplastic astrocytes and promotes FAK activation and invasive/migratory behaviour.
  • Results demonstrate that increased expression and activity of LOX positively correlated with invasive phenotype of malignant astrocytoma cell lines.
  • Immunohistochemistry detected increased LOX within tumour cells and ECM in grade I-IV astrocytic neoplasm compared with normal brain and coincidence of increased LOX with the loss of glial fibrillary acidic protein in higher-grade tumours.
  • These results demonstrate an important LOX-mediated mechanism that promotes migratory/invasive behaviour of malignant astrocytes.
  • [MeSH-minor] Astrocytoma / enzymology. Blotting, Western. Cell Line, Tumor. Cell Movement / physiology. Humans. Immunohistochemistry. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931358.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47713; United States / NCRR NIH HHS / RR / G12RR003096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Paxillin; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


51. Gopalakrishna-Pillai S, Iverson LE: Astrocytes derived from trisomic human embryonic stem cells express markers of astrocytic cancer cells and premalignant stem-like progenitors. BMC Med Genomics; 2010 Apr 27;3:12
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Astrocytes derived from trisomic human embryonic stem cells express markers of astrocytic cancer cells and premalignant stem-like progenitors.
  • Since most hESC-based therapies will utilize differentiated derivatives, it is imperative to investigate the potential of trisomic hESCs to undergo malignant transformation during differentiation prior to their use in the clinical setting.
  • METHODS: Diploid and trisomic hESCs were differentiated into astrocytic progenitors cells (APCs), RNA extracted and hybridized to human exon-specific microarrays.
  • Global gene expression profiles of diploid and trisomic APCs were compared to that of an astrocytoma cell line and glioblastoma samples, analyzed by others, using the same microarray platform.
  • RESULTS: Bioinformatic analysis of microarray data indicates that differentiated trisomic APCs exhibit global expression profiles with similarities to the malignant astrocytoma cell line.
  • An analogous trend is observed in comparison to glioblastoma samples indicating that trisomic APCs express markers of astrocytic cancer cells.
  • The analysis also allowed identification of transcripts predicted to be differentially expressed in brain tumor stem cells.
  • These data indicate that in vitro differentiation of trisomic hESCs along astrocytic pathways give rise to cells exhibiting properties of premalignant astrocytic stem/progenitor cells.
  • This in vitro culture system can be used to elucidate changes in gene expression occurring enroute to malignant transformation and to identify molecular markers of cancer stem/progenitor cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] PLoS Med. 2009 Feb 17;6(2):e1000029 [19226183.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):811-22 [11336704.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4737-45 [12805313.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):53-4 [14661028.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):47-52 [15201957.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4933-8 [15297393.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] J Clin Invest. 1988 Jul;82(1):177-88 [3392206.001]
  • [Cites] Development. 1991 Nov;113(3):755-65 [1821847.001]
  • [Cites] Cancer Lett. 1996 Jun 24;104(1):121-6 [8640738.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):19-20 [15637610.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1094-101 [15459006.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):570-82 [15741319.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Glia. 2005 Dec;52(4):289-300 [16001427.001]
  • [Cites] Blood Rev. 2005 Nov;19(6):321-31 [16275420.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1952-61 [16373710.001]
  • [Cites] Nat Biotechnol. 2006 Mar;24(3):351-7 [16501577.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):531-46 [16293579.001]
  • [Cites] J Pathol. 2006 May;209(1):15-24 [16463268.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82 [16609006.001]
  • [Cites] Cell Biol Int. 2006 Jul;30(7):640-4 [16753311.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8212-8 [17114498.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56 [17146289.001]
  • [Cites] J Neurochem. 2007 Mar;100(6):1515-30 [17286628.001]
  • [Cites] J Physiol. 2007 Jun 15;581(Pt 3):1057-81 [17412766.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5635-42 [17575129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] J Biol Chem. 2007 Oct 26;282(43):31558-68 [17711864.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10103-5 [17974949.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):235-43 [18320068.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jun;47(6):530-42 [18335499.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2897-909 [18037961.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jun 25;288(1-2):111-8 [18420341.001]
  • [Cites] Genetics. 2008 Jun;179(2):737-46 [18558649.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):309-19 [18445700.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Jan 1;188(1):1-25 [19061776.001]
  • [Cites] Surg Neurol. 2008 Dec;70 Suppl 1:S1:4-8; discussion S1:8 [18617237.001]
  • [Cites] Nat Biotechnol. 2009 Jan;27(1):91-7 [19122652.001]
  • [Cites] Ann N Y Acad Sci. 2000;926:122-5 [11193027.001]
  • (PMID = 20423517.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA033572
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2873256
  •  go-up   go-down


52. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, Arivazhagan A, Chandramouli BA, Santosh V, Somasundaram K: Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res; 2010 Nov 5;9(11):5557-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth.
  • Glioblastoma (GBM; grade IV astrocytoma) is the most malignant and common primary brain tumor in adults.
  • Using combination of 2-DE and MALDI-TOF MS, we analyzed 14 GBM and 6 normal control sera and identified haptoglobin α2 chain as an up-regulated serum protein in GBM patients.
  • GBM-specific up-regulation was confirmed by ELISA based quantitation of haptoglobin (Hp) in the serum of 99 GBM patients as against lower grades (49 grade III/AA; 26 grade II/DA) and 26 normal individuals (p = 0.0001).
  • Further validation using RT-qPCR on an independent set (n = 78) of tumor and normal brain (n = 4) samples and immunohistochemcial staining on a subset (n = 42) of above samples showed increasing levels of transcript and protein with tumor grade and were highest in GBM (p = <0.0001 and <0.0001, respectively).
  • Further, we demonstrate that both human glioma and mouse melanoma cells overexpressing Hp showed increased tumor growth.
  • Thus, we have identified haptoglobin as a GBM-specific serum marker with a role on glioma tumor growth and migration.
  • [MeSH-minor] Animals. Astrocytes / chemistry. Astrocytes / pathology. Biomarkers, Tumor / blood. Case-Control Studies. Cell Line, Tumor. Cell Movement. Cell Proliferation. Humans. Melanoma / chemistry. Melanoma / pathology. Mice. Up-Regulation

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20822092.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HP protein, human; 0 / Haptoglobins
  •  go-up   go-down


53. Gole B, Durán Alonso MB, Dolenc V, Lah T: Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res; 2009 Dec;15(4):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reportedly, the expression of cathepsins B, L and S gradually increases in the progression from benign astrocytoma to the malignant glioblastoma, although their specific roles in glioma progression have not been revealed.
  • The differences between the matrix invading cells and non-invading core cells from spheroids derived from glioblastoma cell culture and from glioblastoma patients' biopsies, and embedded in type I collagen, have been studied at the mRNA, protein and cathepsin activity levels.
  • [MeSH-minor] Adult. Aged. Cathepsin L / metabolism. Cathepsins / metabolism. Cell Line, Tumor. Collagen / metabolism. Cystatins / metabolism. Drug Combinations. Female. Humans. Laminin / metabolism. Male. Middle Aged. Neoplasm Invasiveness / physiopathology. Proteoglycans / metabolism. Spheroids, Cellular / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434518.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cystatins; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.- / Cathepsins; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.27 / cathepsin S
  •  go-up   go-down


54. Winters BS, Shepard SR, Foty RA: Biophysical measurement of brain tumor cohesion. Int J Cancer; 2005 Apr 10;114(3):371-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biophysical measurement of brain tumor cohesion.
  • An advantage of using 3D multicellular spheres to study tumor biology is that they better approximate the interactions encountered by cells in vivo.
  • This liquid-like behavior enables us to measure a key property influencing tumor behavior, namely, intercellular cohesion.
  • This study utilizes TST to measure the cohesivity of 3 widely used malignant astrocytoma cell lines of different in vitro invasive potentials.
  • We show that the cell lines exhibit liquid-like behavior since they form spheroids whose surface tension is both force- and volume-independent; that aggregates from each cell line have a distinct surface tension that correlates with their in vitro invasive capacity; that dexamethasone (Dex), a widely used therapeutic agent for the treatment of tumor-related cerebral edema, increases aggregate cohesivity and decreases invasiveness; that dexamethasone treatment decreases invasion in a dose-dependent manner but only when cells are in direct contact with one another; and that dex-mediated decreased invasiveness correlates with increased aggregate cohesivity as measured by TST but not with N-cadherin expression or function.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Adhesion. Models, Biological. Neoplasm Invasiveness / physiopathology. Spheroids, Cellular

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15551307.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


55. Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jäkel O, Jensen A, Klemm S, Münter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J: Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncol; 2010 Oct;49(7):1132-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Main treated indications consisted of skull base chordoma (n = 9) and chondrosarcoma (n = 18), malignant salivary gland tumors (n=29), chordomas of the sacrum (n = 5), low grade glioma (n=3), primary and recurrent malignant astrocytoma and glioblastoma (n=7) and well as osteosarcoma (n = 3).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20831505.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 0 / Protons; 7440-44-0 / Carbon
  •  go-up   go-down


56. Ulrich TA, de Juan Pardo EM, Kumar S: The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res; 2009 May 15;69(10):4167-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is a malignant astrocytoma of the central nervous system associated with a median survival time of 15 months, even with aggressive therapy.
  • This rapid progression is due in part to diffuse infiltration of single tumor cells into the brain parenchyma, which is thought to involve aberrant interactions between tumor cells and the extracellular matrix (ECM).
  • Here, we test the hypothesis that mechanical cues from the ECM contribute to key tumor cell properties relevant to invasion.
  • We cultured a series of glioma cell lines (U373-MG, U87-MG, U251-MG, SNB19, C6) on fibronectin-coated polymeric ECM substrates of defined mechanical rigidity and investigated the role of ECM rigidity in regulating tumor cell structure, migration, and proliferation.
  • On highly rigid ECMs, tumor cells spread extensively, form prominent stress fibers and mature focal adhesions, and migrate rapidly.
  • As ECM rigidity is lowered to values comparable with normal brain tissue, tumor cells appear rounded and fail to productively migrate.
  • Collectively, our results provide support for a novel model in which ECM rigidity provides a transformative, microenvironmental cue that acts through actomyosin contractility to regulate the invasive properties of GBM tumor cells.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biophys J. 2008 Nov 1;95(9):4426-38 [18658232.001]
  • [Cites] Curr Biol. 2008 Sep 9;18(17):1295-9 [18718759.001]
  • [Cites] Biophys J. 2008 Dec;95(11):5374-84 [18775961.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Mar;45(3):185-99 [10706774.001]
  • [Cites] Biotechnol Bioeng. 2000 Aug 20;69(4):359-69 [10862674.001]
  • [Cites] Biophys J. 2000 Jul;79(1):144-52 [10866943.001]
  • [Cites] Med Biol Eng Comput. 2000 May;38(3):360-70 [10912355.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Nov;279(5):C1345-50 [11029281.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):9-15 [11918088.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8861-9 [14654782.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):982-9 [14699073.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):275-82 [8760599.001]
  • [Cites] J Cell Sci. 1996 Mar;109 ( Pt 3):643-52 [8907709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13661-5 [9391082.001]
  • [Cites] Nat Med. 1999 Feb;5(2):221-5 [9930872.001]
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):231-9 [10090669.001]
  • [Cites] Cell Motil Cytoskeleton. 2005 Jan;60(1):24-34 [15573414.001]
  • [Cites] Cell Motil Cytoskeleton. 2005 Mar;60(3):153-65 [15662725.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2411-22 [15800333.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):198-209 [15669099.001]
  • [Cites] Biophys J. 2005 Jul;89(1):635-50 [15849239.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8792-800 [16204049.001]
  • [Cites] Science. 2005 Nov 18;310(5751):1139-43 [16293750.001]
  • [Cites] J Neurosci Res. 2006 Feb 1;83(2):243-55 [16385577.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):235-53; discussion 253 [16362178.001]
  • [Cites] Biophys J. 2006 Apr 15;90(8):3012-8 [16461391.001]
  • [Cites] Biophys J. 2006 May 15;90(10):3762-73 [16500961.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10889-94 [16832052.001]
  • [Cites] Cell. 2006 Aug 25;126(4):677-89 [16923388.001]
  • [Cites] Biophys J. 2006 Oct 1;91(7):2708-16 [16829558.001]
  • [Cites] Neurosci Lett. 2006 Oct 23;407(2):124-6 [16978776.001]
  • [Cites] Curr Biol. 2006 Oct 10;16(19):1962-7 [17027494.001]
  • [Cites] Biophys J. 2006 Nov 15;91(10):3907-20 [16920834.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11709-17 [17178866.001]
  • [Cites] Cell Mol Life Sci. 2007 Feb;64(4):458-78 [17260089.001]
  • [Cites] J Neurotrauma. 2007 May;24(5):812-22 [17518536.001]
  • [Cites] Mol Carcinog. 2007 Jun;46(6):488-96 [17219439.001]
  • [Cites] Acta Biomater. 2007 Jul;3(4):413-38 [17540628.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):368-76 [17492663.001]
  • [Cites] Neoplasma. 2007;54(6):517-26 [17949236.001]
  • [Cites] Cell Motil Cytoskeleton. 2008 Jan;65(1):12-24 [17896341.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1862-71 [18339867.001]
  • [Cites] Nat Clin Pract Oncol. 2008 May;5(5):280-90 [18349857.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Aug;17(8):1225-35 [18616418.001]
  • [Cites] Mol Biol Cell. 2008 Aug;19(8):3357-68 [18495866.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • (PMID = 19435897.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIH HHS / OD / DP2 OD004213; United States / NIH HHS / OD / OD004213-01; United States / NIH HHS / OD / 1DP2OD004213; United States / NIH HHS / OD / DP2 OD004213-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibronectins; 9013-26-7 / Actomyosin
  • [Other-IDs] NLM/ NIHMS105478; NLM/ PMC2727355
  •  go-up   go-down


57. Serrano J, Rayo JI, Infante JR, Domínguez L, García-Bernardo L, Durán C, Fernández Portales I, Cabezudo JM: Radioguided surgery in brain tumors with thallium-201. Clin Nucl Med; 2008 Dec;33(12):838-40
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Malignant astrocytomas show thallium uptake with a high target-to-background ratio, allowing the use of radioguided surgery.
  • METHOD: We report on 6 patients (3 men) diagnosed with malignant astrocytoma.
  • With the gamma probe we confirmed the tumor uptake, and a biopsy sample was taken.
  • After conventional tumor resection, we scanned the surgical bed with the gamma probe.
  • RESULTS: In all patients the biopsy confirmed a high-grade astrocytoma.
  • In all cases we found residual uptake in the surgical bed that was confirmed as residual tumor by pathologic examination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033782.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


58. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A: Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery; 2009 Sep;65(3):463-9; discussion 469-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Balancing the benefits of extensive tumor resection with the consequence of potential postoperative deficits remains a challenge in malignant astrocytoma surgery.


59. Omar AI, Mason WP: Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid; 2010 Jun 15;4:93-111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.
  • INTRODUCTION: Malignant gliomas are a heterogeneous group of primary central nervous system neoplasms that represent less than 2% of all cancers yet carry a significant burden to society.
  • Temozolomide (TMZ) is a new second generation DNA alkylating agent that has become part of malignant astrocytoma management paradigms because of its proven efficacy, ease of administration, and favorable toxicity profile.
  • AIMS: To review the role of TMZ in the management of malignant astrocytomas (World Health Organization grades III and IV) including newly diagnosed (n) and recurrent (r) anaplastic astrocytomas (AA) and glioblastomas.
  • EVIDENCE REVIEW: A series of pivotal clinical trials have established a role for TMZ in the treatment of malignant astrocytomas.
  • A recent large prospective randomized phase III trial showed that the addition of TMZ during and after radiation therapy (RT) in newly diagnosed (nGBM) patients prolonged median overall survival by 2.5 months; perhaps more importantly, the 2-year survival rate for patients receiving TMZ and RT was 26% compared with 10% for those receiving RT alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2000 May 16;132(10):769-79 [10819699.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2098-105 [15389472.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):899-904 [10854567.001]
  • [Cites] Cancer. 2003 May 1;97(9):2262-6 [12712481.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1598-604 [15117981.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2372-7 [15800329.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1583-8 [15051755.001]
  • [Cites] J Oncol Pharm Pract. 2006 Jun;12(2):105-11 [16984749.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Neurosurgery. 1998 Aug;43(2):398-9 [9696102.001]
  • [Cites] Neuro Oncol. 2002 Jan;4(1):39-43 [11772431.001]
  • [Cites] Cancer. 2004 May 15;100(10):2208-14 [15139066.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):191-200 [15072467.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Trends Biochem Sci. 1995 Oct;20(10):421-6 [8533156.001]
  • [Cites] Health Technol Assess. 2001;5(13):1-73 [11359682.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):771-3 [17550757.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):764-72 [10048980.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):499-502 [15166625.001]
  • [Cites] Brain Pathol. 1995 Apr;5(2):145-51 [7670655.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jun;3(6):339-43; quiz following 343 [16757971.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):483-6 [16730911.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):189-95 [15831237.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):124-37 [11550308.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):163-9 [11285554.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1593-607 [17134364.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] N Engl J Med. 2007 Apr 12;356(15):1527-35 [17429084.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):4-5 [16314613.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Oncology (Williston Park). 1998 Apr;12(4):537-43, 547; discussion 547-8, 553 [9575527.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Oncology. 2002;63(1):38-41 [12187069.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):380-6 [15667956.001]
  • [Cites] No Shinkei Geka. 1992 Apr;20(4):493-7 [1570077.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):169-76 [11550311.001]
  • [Cites] Acta Oncol. 2004;43(6):579-84 [15370616.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):589-600 [9681071.001]
  • [Cites] J BUON. 2002 Jan-Mar;7(1):35-41 [17577258.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] Br J Neurosurg. 2002 Aug;16(4):335-42 [12389885.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):942-9 [15870090.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):664-71 [10900246.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4675-86 [17214326.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):1-9 [2661738.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neurochir (Wien). 2003 Jan;145(1):5-10 [12545256.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Qual Life Res. 1996 Dec;5(6):555-67 [8993101.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):295-303 [17001519.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Biochemistry. 1994 Aug 9;33(31):9045-51 [8049205.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1712-6 [15073861.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):606-11 [12478010.001]
  • [Cites] N Engl J Med. 1977 Mar 31;296(13):716-21 [402576.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84 [10837964.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Anticancer Drugs. 1997 Jan;8(1):92-7 [9147618.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1038-44 [15305187.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41 [8892469.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):38-43 [14769139.001]
  • [Cites] Neuroepidemiology. 2006;27(1):55-6 [16825795.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):248-51 [12865911.001]
  • [Cites] Curr Mol Med. 2003 Feb;3(1):73-84 [12558076.001]
  • [Cites] J Neurooncol. 1994;21(2):135-40 [7861189.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1383-8 [11870183.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1788-95 [10974627.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):203-8 [15015788.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Pharmacoeconomics. 2005;23(8):803-15 [16097842.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):85-9 [17031555.001]
  • [Cites] J Health Econ. 1988 Sep;7(3):289-90 [10291478.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Int J Radiat Biol. 2002 Oct;78(10):931-6 [12465658.001]
  • (PMID = 20694068.001).
  • [ISSN] 1555-175X
  • [Journal-full-title] Core evidence
  • [ISO-abbreviation] Core Evid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2899776
  • [Keywords] NOTNLM ; anaplastic astrocytoma / evidence / glioblastoma / glioma / malignant astrocytoma / temozolomide
  •  go-up   go-down


60. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J: Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle; 2008 Aug 15;7(16):2553-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and progression of malignant brain tumors.
  • Given the significance of tumor microenvironment in general, and the established role of paracrine VEGF signaling in glioblastoma (GBM) biology in particular, we explored the potential autocrine control of human astrocytoma behavior by VEGF.
  • Using a range of cell and molecular biology approaches to study a panel of astrocytoma (grade III and IV/GBM)-derived cell lines and a series of clinical specimens from low- and high-grade astrocytomas, we show that co-expression of VEGF and VEGF receptors (VEGFRs) occurs commonly in astrocytoma cells.
  • Blockade of VEGFR2 by the selective inhibitor (SU1498) abrogated the VEGF-mediated enhancement of astrocytoma cell growth and viability under unperturbed culture conditions.
  • In addition, such interference with VEGF-VEGFR2 signaling potentiated the ionizing radiation-induced tumor cell death.
  • In clinical specimens, both VEGFRs and VEGF were co-expressed in astroglial tumor cells, and higher VEGF expression correlated with tumor progression, thereby supporting the relevance of functional VEGF-VEGFR signaling in vivo.
  • Overall, our results are consistent with a potential autocrine role of the VEGF-VEGFR2 (KDR) interplay as a factor contributing to malignant astrocytoma growth and radioresistance, thereby supporting the candidacy of this signaling cascade as a therapeutic target, possibly in combination with radiotherapy.
  • [MeSH-minor] Autocrine Communication. Cell Cycle. Cell Line, Tumor. Humans. Radiation Tolerance. Signal Transduction

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719373.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


61. Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, Laterra J: Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res; 2008 Jan;6(1):139-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal growth factor receptor (EGFR) and c-Met are frequently coexpressed in cancers, including those associated with hepatocyte growth factor (HGF) overexpression, such as malignant astrocytoma.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jun;43(2):127-35 [10533724.001]
  • [Cites] Trends Mol Med. 2005 Jun;11(6):284-92 [15949770.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8806-11 [10722725.001]
  • [Cites] Oncogene. 2000 Apr 27;19(18):2212-23 [10822371.001]
  • [Cites] Mol Cell Biol Res Commun. 1999 Aug;2(2):111-8 [10542134.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4277-83 [10945642.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33937-44 [10938266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8 [11416216.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6387-94 [11533228.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Sci STKE. 2000 Jan 18;2000(15):pe1 [11865189.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2703-15 [11909963.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6329-36 [12414665.001]
  • [Cites] Brain Pathol. 2003 Jan;13(1):52-61 [12580545.001]
  • [Cites] EMBO Rep. 2003 Feb;4(2):166-71 [12612606.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1405-12 [12649206.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39931-40 [12890682.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7345-55 [14612533.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):414-20 [14573593.001]
  • [Cites] FEBS Lett. 2004 May 7;565(1-3):139-42 [15135067.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):8981-93 [15456872.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):317-24 [8106568.001]
  • [Cites] J Biol Chem. 1996 Nov 1;271(44):27456-61 [8910327.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Oct 29;239(3):639-44 [9367820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1415-20 [9990038.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56 [10491431.001]
  • [Cites] Inflammopharmacology. 2004;12(3):233-45 [15527548.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9173-82 [15516982.001]
  • [Cites] Curr Top Microbiol Immunol. 2004;286:1-20 [15645708.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):550-61 [15548598.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4479-86 [15958633.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):172-87 [16014887.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):275-8 [15923382.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] Mol Cells. 2005 Oct 31;20(2):263-70 [16267402.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Mol Carcinog. 2005 Dec;44(4):262-73 [16167350.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1292-8 [16489086.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1347-55 [16391241.001]
  • [Cites] Future Oncol. 2005 Apr;1(2):221-34 [16555994.001]
  • [Cites] Cancer Sci. 2006 May;97(5):341-7 [16630129.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • (PMID = 18234969.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS032148; United States / NINDS NIH HHS / NS / R01 NS043987; United States / NINDS NIH HHS / NS / NS043987-03; United States / NIEHS NIH HHS / ES / ES 09169; United States / NIEHS NIH HHS / ES / R01 ES009169; United States / NINDS NIH HHS / NS / NS 43987; United States / NINDS NIH HHS / NS / NS 32148; United States / NINDS NIH HHS / NS / R01 NS032148-13; United States / NINDS NIH HHS / NS / R01 NS043987-03; United States / NINDS NIH HHS / NS / NS032148-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ligands; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Transforming Growth Factor alpha; 21820-51-9 / Phosphotyrosine; 67256-21-7 / Hepatocyte Growth Factor; 92092-36-9 / CRM197 (non-toxic variant of diphtheria toxin); EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS135584; NLM/ PMC2839502
  •  go-up   go-down


62. Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG: Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol; 2005 Aug 20;23(24):5493-500
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: One hundred thirty-four patients (73 male; mean age +/- standard deviation, 11.8 +/- 5.4 years; 55 had low-grade glioma, 32 had medulloblastoma/primitive neuroectodermal tumor/embryonal tumor, 17 had malignant astrocytoma, nine had germ-cell tumor, and 21 had other types of tumors) were assessed, each in less than 20 minutes.
  • Patients with low-grade glioma were reported to have the highest total HRQOL.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Aug 20;23(24):5424-6 [16110000.001]
  • (PMID = 16110009.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Garcés-Ambrossi GL, McGirt MJ, Mehta VA, Sciubba DM, Witham TF, Bydon A, Wolinksy JP, Jallo GI, Gokaslan ZL: Factors associated with progression-free survival and long-term neurological outcome after resection of intramedullary spinal cord tumors: analysis of 101 consecutive cases. J Neurosurg Spine; 2009 Nov;11(5):591-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, factors associated with tumor resectability, tumor recurrence, and long-term neurological outcome are poorly understood.
  • Pathological type included ependymoma in 51 cases, hemangioblastoma in 15, pilocytic astrocytoma in 16, WHO Grade II astrocytoma in 10, and malignant astrocytoma in 9.
  • Independent of histological tumor type, an intraoperatively identifiable tumor plane (OR 25.3, p < 0.0001) and decreasing tumor size (OR 1.2, p = 0.05) were associated with GTR.
  • In 31 patients (31%) tumor progression developed by last follow-up (mean 19 months).
  • Tumor histology (p < 0.0001) and the presence of an intraoperatively identified tumor plane (hazard ratio [HR] 0.44, p = 0.027) correlated with improved PFS.
  • A GTR resulted in improved PFS for hemangioblastoma (HR 0.004, p = 0.04) and ependymoma (HR 0.2, p = 0.02), but not astrocytoma.
  • The presence of an identifiable tumor plane (HR 3.1, p = 0.0004) and improvement in neurological symptoms before discharge (HR 2.3, p = 0.004) were associated with overall neurological improvement by last follow-up (mean 19 months).
  • CONCLUSIONS: Gross-total resection can be safely achieved in the vast majority of IMSCTs when an intraoperative plane is identified, independent of pathological type.
  • A GTR should be attempted for ependymoma and hemangioblastoma, but it may not affect PFS for astrocytoma.
  • For all tumors, the intraoperative finding of a clear tumor plane of resection carries positive prognostic significance across all pathological types.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Disease Progression. Disease-Free Survival. Ependymoma / mortality. Ependymoma / pathology. Ependymoma / surgery. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests. Prognosis. Recovery of Function. Retrospective Studies. Risk Factors. Therapeutics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Spine. 2009 Nov;11(5):588-9; discussion 590 [19929362.001]
  • (PMID = 19929363.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Adam Y, Benezech J, Blanquet A, Fuentes JM, Bousigue JY, Debono B, Duplessis E, Espagno C, Plas JY, Lescure JP, Destandau J, Hladky JP, Grunewald P, Mahla K, Remond J, Louis E: [Intramedullary tumors. Results of a national investigation in private neurosurgery]. Neurochirurgie; 2010 Aug;56(4):344-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL: Seventy-nine cases were distributed in the following manner: ependymomas, 38; astrocytomas, 22; oligodendrogliomas, four; gangliogliomas, two; hemangioblastomas, 10 (nine sporadic cases and one case of Von Hippel-Lindau disease); primitive melanoma, one; and intramedullary neurinomas, two.
  • Tumor removal was complete in the cases of ependymoma and hemangioblastoma and subtotal in the cases of astrocytoma.
  • Astrocytomas: 22 cases, with 14 cases of astrocytoma, two pilocytic astrocytoma, four malignant astrocytoma, and two glioblastoma.
  • Diagnostic delay: malignant tumors, one to nine months; low grades; three to six years (range, eight months to 25 years).
  • [MeSH-minor] Adolescent. Adult. Aged. Delayed Diagnosis. Female. Follow-Up Studies. France / epidemiology. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20097390.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


65. Nakamura M, Tsuji O, Fujiyoshi K, Watanabe K, Tsuji T, Ishii K, Matsumoto M, Toyama Y, Chiba K: Cordotomy for patients with thoracic malignant astrocytoma. J Neurosurg Spine; 2010 Oct;13(4):418-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cordotomy for patients with thoracic malignant astrocytoma.
  • OBJECT: The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment.
  • In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure.
  • METHODS: Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA).
  • In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection.
  • In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later.
  • One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma.
  • In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF.
  • If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.
  • [MeSH-major] Astrocytoma / surgery. Cordotomy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Encephalitis / etiology. Female. Glioblastoma / complications. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pain, Postoperative. Paraplegia / etiology. Paraplegia / surgery. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887138.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. National Toxicology Program: Toxicology and carcinogenesis studies of divinylbenzene-HP (Cas No. 1321-74-0) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser; 2006 Nov;(534):1-290
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of malignant glial cell tumors (malignant astrocytoma and oligodendroglioma) in the brain were slightly increased in 100 and 200 ppm males, and the incidence in the 200 ppm group exceeded the historical range for chamber controls.
  • [MeSH-major] Neoplasms, Experimental / chemically induced. Vinyl Compounds / toxicity

  • Hazardous Substances Data Bank. VINYLSTYRENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342197.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vinyl Compounds; IZ715T4SBU / divinyl benzene
  •  go-up   go-down


67. Ooba H, Abe T, Kamida T, Anan M, Momii Y, Tokuuye K, Fujiki M: Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1641-3
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • To our knowledge, malignant fibrous histiocytosis caused by proton therapy has not been reported, therefore the clinical features of this complication are described and previous cases are reviewed.
  • [MeSH-minor] Aged. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766005.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


68. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A: Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther; 2006 Sep-Oct;13(5):458-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
  • Astrocytomas are central nervous system neoplasms, which are derived predominately from astrocytes.
  • On the basis of the histopathologic characteristics astrocytomas are graded from I to IV.
  • The cells that demonstrate the greatest degree of anaplasia are used to determine the histologic grade of the tumor.
  • The mean age of survival are approximately 10 years from the time of diagnosis for pilocystic astrocytomas (World Health Organization grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II), 2 to 5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV).
  • The treatment is a combination of surgery, radiation, and chemotherapy depending of the grade of astrocytoma.
  • We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988542.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Preusser M, Haberler C, Hainfellner JA: Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr; 2006 Jun;156(11-12):332-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant glioma: neuropathology and neurobiology.
  • Malignant gliomas may manifest at any age including congenital and childhood cases.
  • Malignant gliomas comprise a spectrum of different tumor subtypes.
  • Within this spectrum, glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma share as basic features preferential location in cerebral hemispheres, diffuse infiltration of brain tissue, fast tumor growth with fatal outcome within months or years.
  • Vascular proliferates and tissue necrosis are characteristic features of malignant gliomas, in particular glioblastoma.
  • These features are most likely the consequence of rapidly increasing tumor mass that is inadequately oxygenized by the preexisting vasculature.
  • In malignant glioma, distinct molecular pathways including the p53 pathway, the RB pathway and the EGFR pathway show frequent alterations that seem to be pathogenetically relevant.
  • Methylguanine-methyltransferase (MGMT) promoter methylation status in glioblastoma and 1p19q deletion status in anaplastic oligodendroglioma are associated with response to chemotherapy.
  • [MeSH-minor] Adult. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Chromosome Aberrations. Female. Humans. Infant. Male. Neoplasm Invasiveness / pathology. Prognosis


70. Kawai H, Ishikawa T, Moroi J, Hanyu N, Sawada M, Kobayashi N, Mutou T, Hikichi K, Suzuki A, Yasui N, Yoshida Y: [Elderly patient with cerebellar malignant astrocytoma]. No Shinkei Geka; 2008 Sep;36(9):799-805
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elderly patient with cerebellar malignant astrocytoma].
  • Malignant cerebellar astrocytoma is very rare and the prognosis is extremely poor.
  • We report herein the case of an elderly patient with malignant cerebellar astrocytoma.
  • Metastatic cerebellar tumor was diagnosed on first admission, based on a past history of colon cancer treated by surgery and magnetic resonance imaging (MRI) findings supporting the diagnosis of metastasis.
  • The tumor represented malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800635.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


71. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D: Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol; 2005 Dec;181(12):768-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT).
  • PURPOSE: To assess the effect of reirradiation in recurrent WHO grade III astrocytomas.
  • PATIENTS AND METHODS: From January 1995 to July 2003, 40 patients with grade III gliomas were treated with fractionated stereotactic reirradiation at the time point of recurrence.
  • No toxicities > CTC grade 2 developed.
  • CONCLUSION: Fractionated stereotactic radiotherapy is well tolerated and effective in patients with recurrent grade III astrocytomas.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / surgery. Brain Neoplasms / mortality. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Radiosurgery / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362786.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Menon G, Nair S, Rajesh BJ, Rao BR, Radhakrishnan VV: Malignant astrocytoma following radiotherapy for craniopharyngioma. J Cancer Res Ther; 2007 Jan-Mar;3(1):50-2
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytoma following radiotherapy for craniopharyngioma.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Craniopharyngioma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Pituitary Neoplasms / radiotherapy. Radiotherapy / adverse effects


73. Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M: Molecular biology of malignant gliomas. Clin Transl Oncol; 2006 Sep;8(9):635-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of malignant gliomas.
  • For example, gliomas of astrocytic origin (astrocytomas) are classified into pilocytic astrocytoma (grade I), astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (GMB) (grade IV).
  • Tumors derived from oligodendrocytes include grade II (oliogodendrogliomas) and grade III neoplasms (oligoastrocytoma).
  • Obviously, prognosis and biological behaviour of malignant gliomas are closely related and supported by the different molecular background that possesses each type of glioma.
  • Furthermore, the ability that allows several low-grade gliomas to progress into more aggressive tumors has allowed cancer researchers to elucidate several pathways implicated in molecular biology of these devastating tumors.
  • In this review, we describe classical pathways involved in human malignant gliomas with special focus with recent advances, such as glioma stem-like cells and expression patterns from microarray studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005465.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 36
  •  go-up   go-down


74. van den Boom J, Wolter M, Blaschke B, Knobbe CB, Reifenberger G: Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int J Cancer; 2006 Nov 15;119(10):2330-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction.
  • To identify novel genes involved in glioma progression we performed suppression subtractive hybridization combined with cDNA array analysis on 4 patients with primary low-grade gliomas of World Health Organization (WHO) grade II that recurred as secondary glioblastomas (WHO grade IV).
  • Eight genes showing differential expression between primary and recurrent tumors in 3 of the 4 patients were selected for further analysis using real-time reverse transcription-PCR on a series of 10 pairs of primary low-grade and recurrent high-grade gliomas as well as 42 astrocytic gliomas of different WHO grades.
  • These analyses revealed that 5 genes, i.e., AMOG (ATP1B2, 17p13.1), APOD (3q26.2-qter), DMXL1 (5q23.1) DRR1 (TU3A, 3p14.2) and PSD3 (KIAA09428/HCA67/EFA6R, 8p22), were expressed at significantly lower levels in secondary glioblastomas as compared to diffuse astrocytomas of WHO grade II.
  • In addition, AMOG, DRR1 and PSD3 transcript levels were significantly lower in primary glioblastomas than in diffuse astrocytomas.
  • Sequencing of sodium bisulfite-modified DNA demonstrated AMOG promoter hypermethylation in the glioma cell lines and 1 primary anaplastic astrocytoma with low AMOG expression.
  • Taken together, we identified interesting novel candidate genes that likely contribute to glioma progression and provide first evidence for a role of epigenetic silencing of AMOG in malignant glioma cells.
  • [MeSH-major] Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Cation Transport Proteins / genetics. Cell Adhesion Molecules, Neuronal / genetics. Gene Silencing. Nucleic Acid Hybridization. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Apolipoproteins / genetics. Apolipoproteins D. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Biomarkers, Tumor / genetics. DNA Methylation. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Glycoproteins / genetics. Histone Deacetylases / genetics. Humans. Hydroxamic Acids / pharmacology. Membrane Transport Proteins / genetics. Nerve Tissue Proteins / genetics. Nuclear Proteins / genetics. Oligonucleotide Array Sequence Analysis. Protein Synthesis Inhibitors / pharmacology. Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865689.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / ATP1B2 protein, human; 0 / Antimetabolites, Antineoplastic; 0 / Apolipoproteins; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Cation Transport Proteins; 0 / Cell Adhesion Molecules, Neuronal; 0 / DMXL1 protein, human; 0 / FAM107A protein, human; 0 / Glycoproteins; 0 / Hydroxamic Acids; 0 / Membrane Transport Proteins; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / PSD protein, human; 0 / Protein Synthesis Inhibitors; 0 / Proteins; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3; EC 3.6.1.- / Adenosine Triphosphatases; M801H13NRU / Azacitidine
  •  go-up   go-down


75. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg; 2009 Jan;110(1):156-62
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
  • OBJECT: With recent advances in the adjuvant treatment of malignant brain astrocytomas, it is increasingly debated whether extent of resection affects survival.
  • METHODS: The authors retrospectively reviewed the cases of 1215 patients who underwent surgery for malignant brain astrocytomas (World Health Organization [WHO] Grade III or IV) at a single institution from 1996 to 2006.
  • Surgery consisted of primary resection in 549 patients (58%) and revision resection for tumor recurrence in 400 patients (42%).
  • The lesion was WHO Grade IV in 700 patients (74%) and Grade III in 249 (26%); there were 167 astrocytomas and 82 mixed oligoastrocytoma.
  • Adjusting for factors associated with survival for WHO Grade III astrocytoma (age, KPS score, and revision resection), GTR versus STR (p < 0.05) was associated with improved survival.
  • Gross-total resection versus NTR was not associated with an independent survival benefit in patients with WHO Grade III astrocytomas.
  • The median survival after primary resection of WHO Grade III (mixed oligoastrocytomas excluded) for GTR, NTR, and STR was 58, 46, and 34 months, respectively.
  • CONCLUSIONS: In the authors' experience with both primary and secondary resection of malignant brain astrocytomas, increasing extent of resection was associated with improved survival independent of age, degree of disability, WHO grade, or subsequent treatment modalities used.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847342.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Polyesters; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


76. Tanaka K, Sasayama T, Kawamura A, Kondoh T, Kanomata N, Kohmura E: Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion. Neurol Med Chir (Tokyo); 2006 Apr;46(4):198-201
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.
  • A 30-year-old man presented with a supratentorial malignant glioma manifesting as isolated progressive left oculomotor nerve paresis.
  • Computed tomography and magnetic resonance imaging showed an intra-axial tumor in the left temporal lobe, extending to the basal and prepontine cisterns, and compressing the brainstem.
  • The tumor was removed subtotally.
  • The histological diagnosis was anaplastic astrocytoma.
  • Malignant glioma with exophytic growth in the temporal lobe should be considered in the differential diagnosis of isolated oculomotor nerve paresis.
  • [MeSH-major] Astrocytoma / complications. Oculomotor Nerve Diseases / etiology. Supratentorial Neoplasms / complications. Temporal Lobe
  • [MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636512.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Niizuma K, Fujimura M, Kumabe T, Tominaga T: Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome. J Clin Neurosci; 2007 Jan;14(1):53-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.
  • A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma.
  • The clinical course and histological findings suggest that the parasitic infection and/or genetic changes contributed to the malignant transformation of the astrocytic tumour.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Neurocysticercosis / pathology

  • Genetic Alliance. consumer health - Turcot syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138070.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


78. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB: Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol; 2009 Dec;95(3):377-382
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.
  • Pilocytic astrocytoma is a slow-growing, circumscribed glioma that most frequently occurs within the pediatric population.
  • In general, surgical resection for pilocytic astrocytoma is thought to be curative with tumor recurrence or malignant transformation being relatively rare.
  • However, there have been very few studies specifically looking at the prognosis for adult patients diagnosed with pilocytic astrocytoma.
  • To evaluate the frequency of recurrence and malignant transformation of pilocytic astrocytoma in adults, we performed a retrospective analysis of all adult patients who underwent surgical resection for this tumor at our institution over a period of 10 years.
  • A high rate of malignant transformation was observed in the patients that underwent repeat surgery with 75% (3/4) progressing to anaplastic astrocytoma on pathological examination.
  • This study provides further evidence that the clinical course of a subset of adult patients with pilocytic astrocytoma will not be benign.
  • The potential for rapid tumor recurrence and malignant transformation necessitates careful post-operative follow-up for adult patients with this tumor.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533024.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Lin KC, Cheng TJ, Yung JM, Kuo JR: Malignant astrocytoma following radiation for nasopharyngeal carcinoma: case report and review of the literature. Acta Neurol Taiwan; 2007 Mar;16(1):27-32
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytoma following radiation for nasopharyngeal carcinoma: case report and review of the literature.
  • A 32-year-old woman developed malignant astrocytoma 3 years after radiotherapy for nasopharnygeal carcinoma (NPC).
  • The theoretical risk of tumor induction in neural tissues, following radiotherapy by low-dose radiation has been verified, but the association of radiation-induced brain malignancy and NPC is extremely rare.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486730.001).
  • [ISSN] 1028-768X
  • [Journal-full-title] Acta neurologica Taiwanica
  • [ISO-abbreviation] Acta Neurol Taiwan
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


80. Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE: Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg; 2008 Apr;108(4):642-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.
  • OBJECT: This study was undertaken to evaluate the association between age at diagnosis, patterns of care, and outcome among elderly individuals with anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM).
  • The odds of undergoing various combinations of treatments and the associations with outcome were calculated by tumor type and age and adjusted by various predictors.
  • Very elderly individuals with malignant astrocytomas were more likely to receive limited treatment (most pronounced in individuals with GBM).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2012 Feb;116(2):355-6; discussion 356 [21942728.001]
  • [CommentIn] J Neurosurg. 2008 Apr;108(4):639-40 [18377239.001]
  • (PMID = 18377240.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA101954; United States / NCI NIH HHS / CA / K07-CA91849; United States / NCI NIH HHS / CA / K08-CA101954
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


81. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K: PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther; 2008 May;7(5):663-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
  • Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV).
  • GBM is the most malignant with a median survival of 10-12 months in patients.
  • Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples.
  • Further validation using real time RT-qPCR on an independent set of tumor samples (n=91) and normal brain samples (n=9), GBM specific higher expression of PBEF1 was confirmed.
  • We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade.
  • Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM.
  • Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival.
  • Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor. Brain / metabolism. Brain Neoplasms / metabolism. Cytokines / physiology. Gene Expression Regulation, Neoplastic. Glioblastoma / metabolism. Nicotinamide Phosphoribosyltransferase / metabolism
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Humans. Immunohistochemistry / methods. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728403.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Tumor Suppressor Protein p53; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  •  go-up   go-down


82. Hope AJ, Mansur DB, Tu PH, Simpson JR: Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst; 2006 Sep;22(9):1201-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.
  • INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.
  • DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.
  • The patient is currently alive but with recurrent astrocytoma after a complete remission on temozolomide monotherapy.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570196.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


83. Murakami R, Sugahara T, Nakamura H, Hirai T, Kitajima M, Hayashida Y, Baba Y, Oya N, Kuratsu J, Yamashita Y: Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology; 2007 May;243(2):493-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.
  • PURPOSE: To retrospectively evaluate whether the minimum apparent diffusion coefficient (ADC) of the tumor seen on pretreatment magnetic resonance (MR) images is of prognostic value in patients with malignant supratentorial astrocytoma.
  • Between June 1996 and November 2003, 79 patients (44 male, 35 female; age range, 16-76 years) with malignant supratentorial astrocytoma underwent pretreatment MR imaging.
  • Patient age, symptom duration, neurologic function, mental status, Karnofsky performance scale (KPS) score, extent of surgery, histopathologic diagnosis, tumor component enhancement, and minimum ADC were assessed at factor analysis of survival.
  • RESULTS: Twenty-nine patients had anaplastic astrocytoma, and 50 had glioblastoma multiforme.
  • The minimum ADC was significantly lower in patients with glioblastoma multiforme than in those with anaplastic astrocytoma (P < .001).
  • CONCLUSION: The minimum ADC at pretreatment MR imaging is a useful clinical prognostic biomarker for survival in patients with malignant supratentorial astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Radiotherapy, Adjuvant / methods. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356177.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Finlay JL, Dhall G, Boyett JM, Dunkel IJ, Gardner SL, Goldman S, Yates AJ, Rosenblum MK, Stanley P, Zimmerman RA, Wallace D, Pollack IF, Packer RJ, Children's Cancer Group: Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Dec;51(6):806-11
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
  • PURPOSE: Children and adolescents with malignant astrocytomas recurring after initial treatment have a dismal prognosis, with only rare patients surviving 1-year beyond recurrence.
  • METHODS: Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11).
  • Time to progression and death following myeloablative chemotherapy for these patients was compared non-randomly with outcome of a contemporaneously treated cohort of similar patients who received only conventional chemotherapy following initial tumor progression.
  • Of 56 children with recurrent malignant astrocytoma who received conventional chemotherapy following initial progression, no patient survives.
  • CONCLUSIONS: Myeloablative chemotherapy with autologous marrow rescue can produce durable remissions in children and young adults with recurrent malignant gliomas, in the setting of minimal residual tumor burden achieved surgically.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3569-74 [10629654.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):89-94 [16292488.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):32-7 [11205914.001]
  • [Cites] Acta Neurochir (Wien). 2002 Dec;144(12):1265-70; discussion 1270 [12478337.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Neurosurg. 1981 Apr;54(4):455-60 [6259300.001]
  • [Cites] J Clin Oncol. 1984 May;2(5):432-7 [6726296.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):639-45 [3009725.001]
  • [Cites] J Clin Oncol. 1987 May;5(5):783-9 [3553437.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):779-82 [2852028.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):239-48 [1964962.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):139-44 [1654401.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] J Neurooncol. 1994;19(1):69-74 [7815106.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):389-94 [8704692.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):813-6 [9708950.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • (PMID = 18802947.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013539; United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / CA013539-30; United States / NCI NIH HHS / CA / U10 CA013539-30; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA021765-259003; United States / NCI NIH HHS / CA / P30 CA021765-259003; None / None / / U10 CA098543-06; United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS65899; NLM/ PMC2844080
  • [Investigator] Bleyer A; Khayat A; Sather H; Krailo M; Buckley J; Stram D; Sposto R; Hutchinson R; Matthay K; Gaynon P; Geyer JR; Shurin S; Reaman G; Ortega J; Ruymann F; Weiner M; Blatt J; Lukens J; Wolff L; Neglia J; Lange B; Steinherz P; Breitfeld P; O'Brien R; Cohen H; Fryer C; Wells R; Finklestein J; Feig S; Tannous R; Odom L; Gilchrist G; Barnard D; Wiley J; Ettinger L; Hetherington M; Coccia P; Norris D; Nachman J; Raney B; Baker D; Sanders J; Rausen A; Cairo M
  •  go-up   go-down


85. Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol; 2007;5:89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.
  • BACKGROUND: Malignant gliomas recur even after extensive surgery and chemo-radiotherapy.
  • Interferon-beta has been reported to suppress MGMT in an experimental glioma model.
  • Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.
  • After 6 cycles, the tumor became refractory to TMZ, and the patient was treated with interferon-beta at 3 x 106 international units/body, followed by 5 consecutive days of 200 mg/m2 TMZ in cycles of 28 days.
  • After the second cycle the tumor decreased in size by 50% (PR).
  • The tumor showed further shrinkage after 8 months and the patient's KPS improved from 70% to 100%.
  • The immunohistochemical study of the initial tumor specimen confirmed positive MGMT protein expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3354-60 [10955823.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24 [11290467.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Mar;41(3):115-9; discussion 119-20 [11372553.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):175-81 [11995819.001]
  • [Cites] J Neurosurg. 2003 Dec;99(6):1047-52 [14705733.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7573-9 [16140920.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Sep;33(9):1279-85 [16969025.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1253-60 [17089046.001]
  • [Cites] J Interferon Res. 1990 Apr;10(2):141-51 [2140395.001]
  • [Cites] J Interferon Res. 1987 Jun;7(3):301-11 [3497213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562-6 [7753843.001]
  • [Cites] Neurol Res. 2000 Dec;22(8):802-8 [11149242.001]
  • (PMID = 17683572.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1976115
  •  go-up   go-down


86. Henriksson R, Malmström A, Bergström P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P, Brännström T, Bergenheim AT: High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol; 2006 Jul;78(3):321-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
  • Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma.
  • The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV.
  • For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
  • In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
  • Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
  • In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
  • Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
  • In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Estramustine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598426.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35LT29625A / Estramustine
  •  go-up   go-down


87. Malhan P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
  • Histological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication.
  • However, it has limitations in assessing biological tumor behavior.
  • This study was carried out to compare proliferative indices using proliferating cell nuclear antigen (PCNA), extent of p53 expression and micro vessel morphometric parameters in patients with low grade and anaplastic astrocytoma.
  • Twenty-five patients, each of grade II and grade III astrocytoma were evaluated using monoclonal antibodies to PCNA, p53 protein and factor VIII related antigen.
  • Patients with grade III astrocytoma had higher PCNA and p53 labeling indices as compared with grade II astrocytoma (29.14 plus/minus 9.87% vs. 16.84 plus/minus 6.57%, p 0.001; 18.18 plus/minus 6.14% vs. 6.14 plus/minus 7.23%, p 0.001, respectively).
  • Micro vessel percentage area of patients with grade III astrocytoma was also (4.26 plus/minus 3.70 vs. 1.05 plus/minus 0.56, p 0.001), higher along with other micro vessel morphometric parameters.
  • Discordance between histology and one or more IHC parameters was seen in 5/25 (20%) of patients with grade III astrocytoma and 9/25 (36%) of patients with grade II disease.
  • Increased proliferative fraction, genetic alterations and neovascularization mark biological aggressiveness in astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Neovascularization, Pathologic. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090216.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


88. Kim JH, Choi C, Benveniste EN, Kwon D: TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem Biophys Res Commun; 2008 Dec 5;377(1):195-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells.
  • Matrix metalloproteinase-9 (MMP-9) is an important angiogenic and prognostic factor in malignant tumors.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as the death ligand, which induces preferential apoptosis of transformed tumor cells.
  • We demonstrated that TRAIL induces MMP-9 expression in human astrocytoma cells, which is preceded by activation of extracellular signal-regulated protein kinase (ERK).
  • These findings indicate that TRAIL treatment in human astrocytoma cells leads to the activation of NF-kappaB and subsequent expression of MMP-9, which are dependent on ERK activation.
  • Collectively, these results suggest that TRAIL has alternative biological functions in addition to its role in inducing apoptosis in human malignant astrocytoma cells.
  • [MeSH-major] Astrocytoma / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Matrix Metalloproteinase 9 / biosynthesis. TNF-Related Apoptosis-Inducing Ligand / physiology
  • [MeSH-minor] Butadienes / pharmacology. Cell Line, Tumor. Enzyme Activation. Humans. NF-kappa B / metabolism. Nitriles / pharmacology. Protein Kinase Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834856.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / NF-kappa B; 0 / Nitriles; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / U 0126; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


89. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T: Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol; 2007 Jan;17(1):5-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
  • The aim of the present study was to elucidate genetic alterations that are critically involved in astrocytoma progression.
  • We characterized 27 World Health Organization grade II fibrillary astrocytomas which later underwent recurrence or progression, paying specific attention to the CpG island methylation status of critical growth regulatory genes. p14(ARF) and O(6)-methylguanine-DNA methyltransferase (MGMT) hypermethylation represented frequent events (26% and 63%, respectively), which were mutually exclusive except in one case, with alternate or simultaneous methylation of these two genes occurring in 85% of our tumor series.
  • Methylation of the p21(Waf1/Cip1), p27(Kip1) and p73 genes and homozygous deletion of the p16(INK4a), p15(INK4b) and p14(ARF) genes were not detected in any of the primary low-grade tumors.
  • Examination of 20 cases whose histological data for recurrent tumors were available revealed that malignant progression occurred in all of the tumors with p14(ARF) methylation but less frequently (50%) in the lesions with MGMT methylation.
  • On analysis of their respective recurrent tumors, five of six patients whose primary low-grade tumors carried p14(ARF) methylation exhibited homozygous co-deletions of the p14(ARF), p15(INK4b) and p16(INK4a) genes, which were restricted to glioblastoma as the most malignant end point.
  • Our findings suggest that p14(ARF) hypermethylation and MGMT hypermethylation constitute distinct molecular pathways of astrocytoma progression, which could differ in biological behavior and clinical outcome.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CpG Islands / physiology. Neoplasm Recurrence, Local / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Tumor Suppressor Protein p14ARF / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Methylation. Middle Aged. Mutation / genetics. Promoter Regions, Genetic / physiology. Survival Analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493032.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


90. Fiorentini G, Giovanis P, Rossi S, Dentico P, Paola R, Turrisi G, Bernardeschi P: A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia. In Vivo; 2006 Nov-Dec;20(6A):721-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia.
  • The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients.
  • Twelve patients with histologically diagnosed malignant glioma entered the study.
  • Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma.
  • ET appears to have some effectiveness in adults with relapsed malignant glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Electric Stimulation Therapy. Glioma / therapy. Hyperthermia, Induced. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203754.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


91. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • These tumors are defined as a variant of glioblastoma, and it can be developed by progression of the malignant glial cell tumors or primary tumors.
  • We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.
  • He underwent an osteoplastic craniotomy with total tumor resection.
  • Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.
  • MRI showed tumor recurrence in the original site of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20466481.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Guan X, Lai S, Lackey J, Shi J, Techavipoo U, Moulding HD, Flanders AE, Andrews DW: Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging. J Magn Reson Imaging; 2008 Dec;28(6):1322-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging.
  • PURPOSE: To seek to distinguish and visualize the different magnetic resonance imaging (MRI) growth patterns among malignant gliomas utilizing visually enhanced diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: Nineteen consecutive patients undergoing image-guided resection of a newly diagnosed malignant glioma underwent add-on acquisition of DTI data based on an Institutional Review Board (IRB)-approved imaging protocol during preoperative MRI scans for routine intraoperative image guidance.
  • Tumor growth patterns were assigned to expansive or mixed/infiltrative classes as described in the companion article (24).
  • Infiltrating tumors were WHO Grade IV astrocytomas and all expansive tumors were either WHO Grade III astrocytomas or WHO Grade II astrocytomas.
  • DTI-based white matter tractography was conducted and the DTI data were fused with anatomical images using an in-house software package we developed to enhance the visualization of the tumor/fiber interface.
  • RESULTS: Out of the 19 tumor patients studied, 11 had infiltrative tumors and the other 8 had expansive tumors.
  • While less clear with 2D axial diffusion color maps, visually enhanced 3D reconstructions of the tumor/fiber interface successfully corroborated distinctive growth patterns.
  • This was particularly evident when viewed in 3D video loops of each tumor/fiber interface.
  • CONCLUSION: We have successfully developed software that visually enhances the anatomic details of the tumor/fiber interface in patients with anaplastic astrocytomas.
  • These data support the existence of a subgroup of patients within the WHO Grade III classification with expansive tumors and a significantly better prognosis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Processing, Computer-Assisted
  • [MeSH-minor] Adult. Aged. Female. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging, Interventional. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025901.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • One year later, the anaplastic astrocytoma was found to have transformed into a glioblastoma multiforme.
  • Fluorescence in situ hybridization analysis and immunohistochemical examinations detected deletions of the lp36 and 19q13 loci, and nuclear accumulation of TP53 protein in the anaplastic oligodendroglioma but not in the glioblastoma multiforme.
  • These findings suggest that central neurocytoma or progenitor cells have the potential for oligodendrocytic and astrocytic transformation with different genetic aberrations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


94. Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, Broniscer A: High-grade astrocytoma in very young children. Pediatr Blood Cancer; 2007 Dec;49(7):888-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma in very young children.
  • BACKGROUND: High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients.
  • PROCEDURE: We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005.
  • Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2).
  • All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing.
  • CONCLUSIONS: Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • [CommentIn] Pediatr Blood Cancer. 2007 Dec;49(7):879-80 [17941062.001]
  • (PMID = 17554787.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Dresemann G: Temozolomide in malignant glioma. Onco Targets Ther; 2010;3:139-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in malignant glioma.
  • Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and the most frequent primary tumor of the central nervous system.
  • Primary resection that is as complete as possible is recommended for malignant glioma.
  • For temozolomide naive GBM and astrocytoma grade III patients with disease progression, temozolomide is still the treatment of choice outside of clinical studies.
  • The role of lower dosed, dose-dense, or continuous regimen with or without drug combination and the role of temozolomide for newly diagnosed astrocytoma grade III and low grade glioma still has to be determined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856849.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2939767
  • [Keywords] NOTNLM ; astrocytoma WHO grade III / glioblastoma multiforme / malignant glioma / temozolomide
  •  go-up   go-down


96. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T: MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res; 2010 Aug 15;16(16):4289-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance.
  • They are implicated in tumorigenesis and function both as tumor suppressors and as oncogenes.
  • The clinical significance of miRNA expression profiles in malignant gliomas remains unclear.
  • EXPERIMENTAL DESIGN: In this study, we examined the expression levels of 365 mature human miRNAs in 12 malignant gliomas, including 8 glioblastomas and 4 anaplastic astrocytomas, using TaqMan real-time quantitative PCR arrays.
  • A validation study was done to corroborate a subset of the results, including expression levels of miR-196a, -196b, -21, and -15b, by analyzing 92 malignant gliomas by conventional real-time PCR.
  • RESULTS: Expression profiles in glioblastomas and anaplastic astrocytomas suggested that 16 miRNAs were candidate markers associated with the malignant progression of gliomas.
  • Both miRNAs showed increased expression levels in glioblastomas relative to both anaplastic astrocytomas and normal brains in the validation study.
  • CONCLUSIONS: Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. MicroRNAs / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601442.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN196 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


97. Freitas MR, de Muzio SD, Pessoa RC, Stávale JN, Borges LR, Malheiros SM: [Diffuse bone marrow metastasis in cerebellar high-grade astrocytoma. A case report]. Rev Neurol; 2009 Mar 1-15;48(5):242-4
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse bone marrow metastasis in cerebellar high-grade astrocytoma. A case report].
  • [Transliterated title] Metastasis difusa de la medula osea en un astrocitoma cerebeloso de alto grado. Un caso clinico.
  • INTRODUCTION: Cerebellar high-grade astrocytoma is uncommon.
  • Although more prone to present cerebrospinal fluid dissemination, the cerebellar location is not particularly related to the occurrence of extra-cranial metastases, which are also unusual in supratentorial malignant gliomas.
  • CASE REPORT: A 46 year-old man with cerebellar anaplastic astrocytoma who developed pancytopenia due to extensive bone marrow metastases.
  • [MeSH-major] Astrocytoma / pathology. Bone Marrow Neoplasms / secondary. Cerebellar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263392.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


98. Yaman E, Buyukberber S, Uner A, Coskun U, Akmansu M, Benekli M, Yamac D, Ozturk B, Kaya AO, Yildiz R, Ozkan S, Gunel N: Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Onkologie; 2008 Jun;31(6):309-13
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
  • BACKGROUND: Surgical resection followed by radiotherapy used to be the standard treatment in malignant gliomas.
  • PATIENTS AND METHODS: Medical records of 64 patients with malignant glioma were reviewed.
  • Median progression-free survival, and overall survival have not yet been reached in the grade III astrocytoma group at a median follow-up of 19 months.
  • 2-year survival rates were 80% and 19% for the grade III astrocytoma, and for the glioblastoma multiforme groups, respectively.
  • Toxicity was mild to moderate with rare grade 4 toxicities.
  • CONCLUSION: Our data suggest that temozolomide is an active regimen for malignant gliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2008 Jun;31(6):300-2 [18547969.001]
  • (PMID = 18547971.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


99. Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr, Gladson CL: ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther; 2007 Mar;6(3):454-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
  • Anti-angiogenic therapies would be particularly beneficial in the treatment of malignant gliomas.
  • Peptides derived from the second type 1 repeat (TSR) of thrombospondin-1 (TSP-1) have been shown to inhibit angiogenesis in non-glioma tumor models and a modified TSR peptide, ABT-510, has now entered into Phase II clinical trials of its efficacy in non-glioma tumors.
  • As microvascular endothelial cells (MvEC) exhibit heterogeneity, we evaluated the ability of the modified TSR peptide (NAcSarGlyValDallolleThrNvalleArgProNHE, ABT-510) to inhibit malignant glioma growth in vivo and to induce apoptosis of brain microvessel endothelial cells (MvEC) propagated in vitro.
  • We found that daily administration of ABT-510 until euthanasia (days 7 to 19), significantly inhibited the growth of human malignant astrocytoma tumors established in the brain of athymic nude mice.
  • Similar results were found using a model in which the established tumor is an intracerebral malignant glioma propagated in a syngeneic mouse model.
  • These findings indicate that ABT-510 should be evaluated as a therapeutic option for patients with malignant glioma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2007 May;6(5):802-4 [17568181.001]
  • (PMID = 17384534.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97110; United States / NCI NIH HHS / CA / CA97247
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD36; 0 / NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt; 0 / Oligopeptides; 0 / Thrombospondins; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


100. Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y: Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun; 2008 Sep 19;374(2):394-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Podocalyxin expression in malignant astrocytic tumors.
  • Recently, we revealed that highly sulfated KS or another mucin-like transmembrane sialoglycoprotein podoplanin/aggrus is upregulated in malignant astrocytic tumors.
  • The aim of this study is to examine the relationship between podocalyxin expression and malignant progression of astrocytic tumors.
  • In this study, 51 astrocytic tumors were investigated for podocalyxin expression using immunohistochemistry, Western blot analysis, and quantitative real-time PCR.
  • Immunohistochemistry detected podocalyxin on the surface of tumor cells in six of 14 anaplastic astrocytomas (42.9%) and in 17 of 31 glioblastomas (54.8%), especially around proliferating endothelial cells.
  • In diffuse astrocytoma, podocalyxin expression was observed only in vascular endothelial cells.
  • Podocalyxin might be associated with the malignant progression of astrocytic tumors, and be a useful prognostic marker for astrocytic tumors.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / pathology. Sialoglycoproteins / analysis
  • [MeSH-minor] Blotting, Western. Humans. Immunohistochemistry. Polymerase Chain Reaction. Prognosis. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639524.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / podocalyxin
  •  go-up   go-down






Advertisement